Record
stringlengths 1
197k
|
|---|
<|newrecord|> nctId: NCT06275503 id: STROKESTOP III briefTitle: STROKESTOP III - Optimized Method for Atrial Fibrillation Screening overallStatus: NOT_YET_RECRUITING date: 2024-02-20 date: 2025-02-28 date: 2026-06-30 date: 2024-02-23 date: 2024-02-23 name: Danderyd Hospital class: OTHER name: Karolinska Institutet name: Landstinget i Värmland briefSummary: Atrial fibrillation is the most common sustained cardiac arrhythmia affecting more than 3% of the adult population. The symptoms of atrial fibrillation can range from asymptomatic to debilitating. It can be permanent in its nature, but also paroxysmal with only short bursts of atrial fibrillation randomly occurring and can therefore remain unnoticed. Atrial fibrillation increases the risk of stroke five fold if left untreated.
|
Screening for atrial fibrillation in elderly populations above age 65 years can result in detection of new atrial fibrillation cases ranging from 0,5% new AF with a single time-point ECG, up to 30% AF if an implantable loop recorder is inserted for 3 years.
|
Currently opportunistic screening using pulse palpation, or a single time-point ECG is recommended by the European Society of Cardiology guidelines. Systematic screening in individuals aged 75 or above, or at a high stroke risk should be considered.
|
Overall, participation in systematic atrial fibrillation screening trials has been shown to be relatively low with almost 50% non-participants. Participants are generally healthier, with higher socioeconomic status, hence the ones who would potentially benefit the most remain absent.
|
Opportunistic screening has shown promising results with higher participation rates and the possibility of better outreach. There is a lack of data from randomized trials on the difference in participation rates in systematic and opportunistic screening approaches when screening with prolonged ECG monitoring. conditions: Atrial Fibrillation conditions: Atrial Fibrillation New Onset studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Cluster randomized trial primaryPurpose: SCREENING masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 2200 type: ESTIMATED name: Screening invitation mode measure: Participation in screening measure: AF detection in opportunistic compared to systematic screening measure: OAC treatment after AF detection measure: Compliance to OAC treatment 1 year after initiation measure: Health economy measure: Composite endpoint of stroke, death and severe bleeding measure: Reminder strategy effect on participation measure: Comparison of automatic ECG analysis (using AI) for detection of AF in a (by AI algorithm classified) high- compared to a low-risk group measure: Application of the FIND-AF algorithm sex: ALL minimumAge: 75 Years maximumAge: 76 Years stdAges: OLDER_ADULT facility: Karolinska Institutet, Dept Med H city: Stockholm zip: 141 86 country: Sweden name: Emma Svennberg, MD PhD role: CONTACT phone: +46739584822 email: [email protected] name: MD PhD role: CONTACT lat: 59.33258 lon: 18.0649 facility: Region Värmland city: Värmland country: Sweden name: Fredrik Carlstedt role: CONTACT lat: 60.83333 lon: 16.5 hasResults: False
|
<|newrecord|> nctId: NCT06275490 id: 181123PER6_3_1 briefTitle: Post Extraction Changes Following Ridge Preservation Using Partially Demineralized Dentin Block Versus L- PRF Block overallStatus: RECRUITING date: 2024-01-01 date: 2024-05-01 date: 2024-11-15 date: 2024-02-23 date: 2024-02-23 name: Cairo University class: OTHER briefSummary: * The aim is to evaluate post extraction hard tissue changes following ridge preservation using partially demineralized dentin block versus L-PRF block in intact socket in the esthetic zone.
|
* The main question: In patients with un restorable tooth, Will ridge preservation using partially demineralized dentin block be more effective than L-PRF block in managing the post extraction hard tissue alterations?
|
* After enrolment, periodontal and radiographic examination and patients with badly un-restorative tooth in the esthetic zone will be identified. These patients will undergo to mesio-distal distance between adjacent teeth, corono-apical height of bone, presence of labial undercut, dehiscence, or fenestration and Relation to adjacent teeth measurements using trans gingival probing technique, and preapical radiograph or CBCT .
|
* In both groups, the desired tooth will be extracted under local anesthesia using peritomies and surgical forceps.
|
* In intervention group: the teeth will be cleaned and dried, and then the dentin will be ground to obtain particles of a certain size then partially demineralize dentin will obtained by using a tooth transformer machine. At the same time, blood samples are collected and processed to obtain fibrin membranes rich in platelets and leukocytes. This tissue is then mixed with partially demineralized dentin to create a solid mass called a "dentin block". During the process of preserving the alveolar bumps after extraction, this solid mass "dentin mass" is placed inside the dental pockets and covered with fibrin membranes rich in platelets and white blood cells, then 5/0 proline suture are used to fix the fibrin membranes and dentin mass in place. After the recovery period "4-6 months", a biopsy is taken for some cases from the site of the operation for histological evaluation during implant placement.
|
* In control group: the same steps as the first group will be used, but by replacing the partially demineralized dental graft with a xenograft.
|
* Outcomes: Radiographic vertical buccal bone changes, vertical Palatal bone changes, horizontal bone changes, Percentage of new vital bone formation, Percentage of residual bone graft, Implant Primary Stability. The results directly postoperative and 4-6 months postoperatively. conditions: Socket Preservation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A Randomized Controlled Pilot Trial primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: Partially Demineralized Dentin Block name: L-PRF block measure: Radiographic vertical bone changes measure: Radiographic horizontal bone changes measure: Percentage of new vital bone formation and residual graft measure: Implant Primary Stability sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Faculty of dentistry Cairo University status: RECRUITING city: Cairo state: Elmanil zip: 4240101 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
|
<|newrecord|> nctId: NCT06275477 id: 29BRC23.0029 briefTitle: 68Gallium-FAPI PET/CT Imaging in Chronic Inflammatory and Fibrotic Diseases acronym: PARADISE overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-04-21 date: 2026-04-21 date: 2024-02-23 date: 2024-02-23 name: University Hospital, Brest class: OTHER briefSummary: This single-center pilot study is designed to explore the preliminary utility of the \[68Ga\] Ga-FAPI imaging agent in positron emission tomography (PET) combined with computed tomography (CT) for a range of chronic inflammatory and fibrosing diseases. The study focuses on the potential of \[68Ga\] Ga-FAPI, a novel radiotracer targeting Fibroblast Activation Protein (FAP), to improve diagnostic accuracy in various medical conditions. Thirteen distinct clinical situations have been selected for this investigation, including rheumatoid arthritis, liver fibrosis, and systemic lupus, among others. This approach aims to ascertain the value of further clinical development in each area and refine the use of this imaging modality in routine care for both initial evaluation and ongoing monitoring of these diseases. conditions: Inflammatory Disease studyType: INTERVENTIONAL phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This is a single-center, descriptive and analytical pilot study, which will be implemented in 13 distinct and independent populations of patients with chronic inflammatory and/or fibrosing disease. primaryPurpose: DIAGNOSTIC masking: NONE count: 390 type: ESTIMATED name: 68Ga-FAPI46 measure: PET uptake intensity measure: [68Ga]Ga-FAPI PET/CT - Pathology evaluation correlation measure: [68Ga]Ga-FAPI PET/CT - Pathology evaluation correlation measure: [68Ga]Ga-FAPI PET/CT - Pathology evaluation correlation measure: [68Ga]Ga-FAPI PET/CT - Pathology evaluation correlation measure: [68Ga]Ga-FAPI PET/CT - Pathology evaluation correlation measure: [68Ga]Ga-FAPI PET/CT - Pathology evaluation correlation measure: [68Ga]Ga-FAPI PET/CT - Others pathology evaluation correlation measure: [68Ga]Ga-FAPI PET/CT - Others pathology evaluation correlation measure: [68Ga]Ga-FAPI PET/CT - Others pathology evaluation correlation measure: [68Ga]Ga-FAPI PET/CT - Others pathology evaluation correlation measure: [68Ga]Ga-FAPI PET/CT - Others pathology evaluation correlation measure: [68Ga]Ga-FAPI PET/CT - Others pathology evaluation correlation measure: [68Ga]Ga-FAPI PET/CT - Biomarkers correlation measure: [68Ga]Ga-FAPI PET/CT - Biomarkers correlation measure: [68Ga]Ga-FAPI PET/CT - Biomarkers correlation measure: [68Ga]Ga-FAPI PET/CT - Biomarkers correlation measure: [68Ga]Ga-FAPI PET/CT - Biomarkers correlation measure: [68Ga]Ga-FAPI PET/CT - Biomarkers correlation measure: [68Ga]Ga-FAPI PET/CT - Functional parameters correlation measure: [68Ga]Ga-FAPI PET/CT - Functional parameters correlation measure: [68Ga]Ga-FAPI PET/CT - Functional parameters correlation measure: [68Ga]Ga-FAPI PET/CT - Functional parameters correlation measure: [68Ga]Ga-FAPI PET/CT - Functional parameters correlation measure: [68Ga]Ga-FAPI PET/CT - Functional parameters correlation measure: [68Ga]Ga-FAPI PET/CT - Imaging characteristics correlation measure: [68Ga]Ga-FAPI PET/CT - Imaging characteristics correlation measure: [68Ga]Ga-FAPI PET/CT - Imaging characteristics correlation measure: [68Ga]Ga-FAPI PET/CT - Imaging characteristics correlation measure: [68Ga]Ga-FAPI PET/CT - Imaging characteristics correlation measure: [68Ga]Ga-FAPI PET/CT - Imaging characteristics correlation measure: [68Ga] Ga-FAPI PET/CT parameters evolution measure: [68Ga] Ga-FAPI PET/CT parameters evolution measure: [68Ga] Ga-FAPI PET/CT / [18F] F-FDG PET/CT comparison measure: [68Ga] Ga-FAPI PET/CT kinetic measure: [68Ga] Ga-FAPI PET/CT kinetic measure: [68Ga] Ga-FAPI PET/CT kinetic sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06275464 id: BT-600-101 briefTitle: BT-600 Single and Multiple Ascending Oral Doses in Healthy Adult Subjects overallStatus: RECRUITING date: 2024-01-11 date: 2024-04 date: 2024-06 date: 2024-02-23 date: 2024-02-23 name: Biora Therapeutics, Inc. class: INDUSTRY briefSummary: This is a randomized, double-blind, placebo-controlled Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BT-600 when administered in single and multiple ascending doses to healthy participants. The study will enroll up to 48 participants, with participation lasting 2-3 weeks in addition to up to 28 days (about 4 weeks) for screening.
|
The purposes of this study are to learn about the safety and tolerability of single and multiple rising oral doses of BT-600, assess the blood and tissue levels of tofacitinib released from BT-600, and assess the body's effects to the study drug following oral doses of BT-600 in blood and tissue in healthy adult participants.
|
BT-600 is a swallowable drug/device combination product designed to deliver a liquid formulation of tofacitinib to the colon and dispense the study drug throughout the colon. BT-600 consists of two components, the drug part containing a reservoir, which will be filled with liquid tofacitinib, and the drive part. The drive part contains the hardware and software that identifies the colon region and then dispenses the drug to the specific region. The device which contains the drug is referred to as the NaviCap™ device. The NaviCap device is approximately the size of a fish oil pill, is made of plastic material known to be safe for ingestion and has rounded ends for ease of swallowing. Liquid tofacitinib in the reservoir is automatically released when the BT-600 localization technology determines that it has reached the colon. BT-600 passes through the colon and the NaviCap device is excreted via a bowel movement. conditions: Healthy studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 48 type: ESTIMATED name: BT-600 name: BT-600 Placebo measure: Adverse Events measure: Pharmacokinetic (PK) Assessments sex: ALL minimumAge: 19 Years maximumAge: 50 Years stdAges: ADULT facility: Celerion status: RECRUITING city: Lincoln state: Nebraska zip: 68502 country: United States lat: 40.8 lon: -96.66696 hasResults: False
|
<|newrecord|> nctId: NCT06275451 id: EssaiClinique_QUALI-RES briefTitle: Qualitative Study of Emotional Regulation in Schizophrenia acronym: QUALI-RES overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2025-01 date: 2026-01 date: 2024-02-23 date: 2024-02-28 name: University Hospital, Grenoble class: OTHER briefSummary: The main aim of this study is to investigate emotional regulation in individuals with schizophrenia using a qualitative methodology (semi-structured interview) and, therefore, from the person's point of view.
|
Given the qualitative nature of the methodology used in this study, the investigators have no specific hypothesis. The investigators have a general hypothesis suggesting that the patients' discourse will enable us to highlight the emotional regulation difficulties described in the literature. conditions: Schizophrenia conditions: Schizophrenia Schizoaffective studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 40 type: ESTIMATED name: Semi-structured interview measure: Emotional regulation in schizophrenia measure: Factors influencing emotional regulation in schizophrenia measure: Improved emotional regulation in schizophrenia measure: Stages of emotional regulation in schizophrenia sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
|
<|newrecord|> nctId: NCT06275438 id: 81829502.903/39 briefTitle: Comparison of Oxytocin Receptor Immunoreactivity in Placentas Obtained From Women Having Cesarean and Natural Birth overallStatus: COMPLETED date: 2018-08-25 date: 2019-07-01 date: 2019-12-01 date: 2024-02-23 date: 2024-02-23 name: Kafkas University class: OTHER briefSummary: Our study examines the effects of oxytocin hormone receptors. mechanisms of placental tissue cells and therefore intrauterine development. It was conducted to investigate the effects on newborn babies apgar score, fontanel openings, birth weights, etc. By collecting data, normal and They were compared between cesarean births by statistical analysis. normal in this regard Based on the hypothesis that there is a difference between labor and cesarean delivery, this study has been made.OXTR primary antibody was used for immunohistochemical examination. There was no significant difference between the groups in terms of histological examination. In the study, it was found that OXTR immunoreactivity was strong in decidual cells and stromal cells in villi. A stronger OXTR immunoreactivity was detected in villous stroma of placenta of the natural birth group compared to the cesarean birth group. Reaction was not observed in syncytotrophoblast cells and syncytial nodes in both groups, but strong immunoreaction was observed fetal endothelial cells and fetal capillaries in both groups. conditions: Healthy Mothers Who Have Had Both Vaginal and Cesarean Deliveries studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: "Our study was conducted on the placentas of 40 women admitted to the obstetrics clinics of Kars Harakani State Hospital and Kafkas University Training and Research Hospital, after obtaining necessary permissions. Out of 40 placentas, 5 were excluded due to blood incompatibility, 2 were excluded due to subsequent diagnosis of chronic conditions (thyroid disorder, Behçet's disease), and 1 was excluded due to the presence of an accessory placenta, resulting in a total of 32 placentas included in the study. Among these, 16 were from women who had undergone normal vaginal delivery (control group), and 16 were from women who had undergone cesarean section (case group). Tissue samples obtained from the placentas were subjected to histological and immunohistochemical methods to obtain various findings primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 32 type: ACTUAL name: The delivery being performed via cesarean section surgery rather than natural childbirth measure: Oksitosin Receptor Immunoreactivity measure: Pearson correlation analysis sex: FEMALE minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: Kafkas Universty city: Kars state: Merkez zip: 36100 country: Turkey lat: 40.59825 lon: 43.08548 hasResults: False
|
<|newrecord|> nctId: NCT06275425 id: 4-2023-0429 briefTitle: Comparison of the Coughing Frequency of Remimazolam Total Intravenous Anesthesia Versus Inhalational Anesthesia overallStatus: COMPLETED date: 2023-06-25 date: 2023-11-29 date: 2023-11-29 date: 2024-02-23 date: 2024-02-23 name: Yonsei University class: OTHER briefSummary: This study is a randomized controlled trial. Adult patients undergoing thyroidectomy under general anesthesia at Severance Hospital and Yonsei Cancer Center are included in tis study. For intervention group, patients receive anesthesia with total intravenous remimazolam, while for control group, patients receive anesthesia with inhalation anesthetic.
|
The primary end point of the study is to determine whether coughing during endotracheal tube extubation is less when anesthesia is maintained with intravenous remimazolam compared to inhalation anesthetics. The secondary end points are cough score (graded into 4 levels), frequency of reoperation due to postoperative bleeding, These include the frequency of hypertension during the extubation process and whether additional painkillers are used in the recovery room. conditions: Thyroid Neoplasm conditions: Cough studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: a single-blinded randomized controlled trial primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 106 type: ACTUAL name: Total intravenous anesthesia with Byfavo name: Inhalation anesthesia with Sevoflurane measure: Proportion of patients not coughing during postoperative extubation measure: Cough score sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, College of Medicine, Yonsei University, city: Seoul country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
|
<|newrecord|> nctId: NCT06275412 id: IRB-23-04-5675 id: 5R01MD018583-02 type: NIH link: https://reporter.nih.gov/quickSearch/5R01MD018583-02 briefTitle: Family Intervention for Black Teens With Type 1 Diabetes acronym: 3Ms overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2028-03 date: 2028-03 date: 2024-02-23 date: 2024-02-23 name: Wayne State University class: OTHER name: National Institute on Minority Health and Health Disparities (NIMHD) briefSummary: The purpose of this study is to conduct a multicenter, randomized effectiveness trial of The 3Ms 2.0 compared to an educational control condition for improving adolescent glycemic control and diabetes-related family relationships and reducing primary caregiver diabetes-related distress among Black adolescents with type 1 diabetes (T1D) and their primary caregivers. The proposed study would develop and test The 3Ms 2.0 adapted intervention when delivered using a mobile health approach (accessed via parents' cell phone). The intervention will also include new family intervention content (videoclips and text messages). conditions: Type 1 Diabetes conditions: Family Relations studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: CARE_PROVIDER count: 216 type: ESTIMATED name: The 3Ms 2.0 Intervention name: Educational Attention Control (EAC) measure: Glycemic Control measure: Caregiver Diabetes Distress measure: Diabetes-Specific Family Conflict measure: Diabetes-Specific Parental Monitoring measure: Diabetes-Specific Family Support measure: Illness Management measure: Intervention Satisfaction sex: ALL minimumAge: 10 Years maximumAge: 14 Years stdAges: CHILD facility: Children's National Hospital city: Washington state: District of Columbia zip: 20010 country: United States name: Angelica Eddington, Ph.D., ABPP role: CONTACT phone: 202-476-2342 email: [email protected] name: Angelica Eddington, Ph.D., ABPP role: SUB_INVESTIGATOR lat: 38.89511 lon: -77.03637 facility: LeBonheur Children's Hospital city: Memphis state: Tennessee zip: 38103 country: United States name: Kristoffer S Berlin, Ph.D. role: CONTACT email: [email protected] name: Kathryn Sumpter, MD role: SUB_INVESTIGATOR name: Kristoffer S Berlin, Ph.D. role: SUB_INVESTIGATOR lat: 35.14953 lon: -90.04898 facility: University of Tennessee Health Science Center-Memphis city: Memphis state: Tennessee zip: 38163 country: United States name: Kristoffer S Berlin, Ph.D. role: CONTACT email: [email protected] name: Kathryn Sumpter, MD role: SUB_INVESTIGATOR name: Kristoffer S Berlin, Ph.D. role: SUB_INVESTIGATOR lat: 35.14953 lon: -90.04898 hasResults: False
|
<|newrecord|> nctId: NCT06275399 id: INTERFORCE briefTitle: Comprehensive Assessment of Morphometric, Functional, Biomechanical and Biological Interactions Between Atherosclerotic Plaque and Platelets Within the Stenosed Coronary Artery acronym: INTERFORCE overallStatus: RECRUITING date: 2023-07-21 date: 2025-07-21 date: 2026-07-21 date: 2024-02-23 date: 2024-02-23 name: Medical University of Warsaw class: OTHER name: National Science Centre, Poland name: University College, London name: Queen Mary University of London briefSummary: The main objective of the present study is to verify, in vivo, whether shear forces computed solely based on coronary angiography and computational fluid dynamics (CFD) techniques are associated with the biomarkers indicating the prothrombotic tendency of circulating blood in situ - distally and proximally to the coronary stenosis. The study will prospectively assess the relationship between i) the value and distribution of shear rate and shear stress (SS) estimated using three-dimensional angiography and CFD techniques, and ii) atherosclerotic plaque characteristics as assessed by optical coherence tomography (OCT), iii) functional parameters of diseased vessels assessed by vessel fractional flow reserve (vFFR), and iv) in situ platelet activation, as expressed by platelet-derived microvesicles (pMVs) and small extracellular vesicles (sEVs), platelet aggregometry and other serum prothrombotic or inflammatory biomarkers sampled within the coronary artery. conditions: Chronic Coronary Syndrome conditions: Atherosclerosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 105 type: ESTIMATED name: OCT examination name: Blood sampling name: Assessment of vFFR and shear stress parameters measure: Correlation between the mean shear rate and shear stress values at the lesion's site and the concentration of pMVs and sEVs sampled in the distal segment of the artery. measure: Correlation between the shear stress measurements at the site of the lesion and the concentration of inflammatory biomarkers in the distal segment of the artery measure: Correlation between the shear stress measurements at the site of the lesion and the platelet reactivity parameters in the distal segment of the artery measure: Correlation between the shear rate and shear stress values at the site of the lesion and the gradient (delta) concentration of the pMVs and sEVs measure: Correlation between the shear rate and shear stress values at the site of the lesion and the gradient (delta) concentration of inflammatory biomarkers measure: Correlation between the shear rate and shear stress values at the site of the lesion and the gradient (delta) of platelet reactivity measure: Concentrations of inflammatory biomarkers categorized by the atherosclerotic plaque morphology and the mean value of shear stress affecting the endothelium at the stenosis site and as well as according to the vessel measure: Platelet reactivity levels categorized by the atherosclerotic plaque morphology and the mean value of shear stress affecting the endothelium at the stenosis site and as well as according to the vessel measure: Concentrations of pMVs and sEVs categorized by the atherosclerotic plaque morphology and the mean value of shear stress affecting the endothelium at the stenosis site and as well as according to the vessel measure: Platelet reactivity levels in blood sampled from the stenosed vs. the non-stenosed coronary artery measure: Concentrations of analyzed pMVs and sEVs in blood sampled from the stenosed vs. the non-stenosed coronary artery measure: Concentrations of analyzed inflammatory biomarkers in blood sampled from the stenosed vs. the non-stenosed coronary artery measure: Correlation between vFFR delta pressure and the delta platelet reactivity in stenosed artery compared to these gradients in a non-stenosed artery in the same patient measure: Correlation between vFFR delta pressure and the delta concentration of the pMVs and sEVs in stenosed artery compared to these gradients in a non-stenosed artery in the same patient measure: Correlation between vFFR delta pressure and the delta concentration of the inflammatory biomarkers in stenosed artery compared to these gradients in a non-stenosed artery in the same patient sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Medical University of Warsaw status: RECRUITING city: Warsaw state: Mazowieckie zip: 02-097 country: Poland name: Mariusz Tomaniak, MD, PhD, Assoc. Prof. role: CONTACT email: [email protected] name: Adrian Bednarek role: CONTACT email: [email protected] name: Mariusz Tomaniak, MD, PhD, Assoc. Prof. role: PRINCIPAL_INVESTIGATOR lat: 52.22977 lon: 21.01178 hasResults: False
|
<|newrecord|> nctId: NCT06275386 id: 2.31/II/24 briefTitle: Drug-Coated Balloon in Native Chronic Total Occlusion Percutaneous Coronary Intervention acronym: IMAGINATION overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-09-01 date: 2025-09-01 date: 2024-02-23 date: 2024-02-23 name: National Institute of Cardiology, Warsaw, Poland class: OTHER briefSummary: The IMAGINATION trial is an investigator-initiated, prospective, single-center study of symptomatic patients with a native chronic total occlusion (CTO) undergoing intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) with a drug-coated balloon (DCB). Post-PCI IVUS and fractional flow reserve (FFR) at baseline and at 6-months follow-up will be performed. In addition, patients included in the coronary computed tomography angiography (CCTA) substudy will undergo photon-counting CCTA at 12-months follow-up. The aim of this study is to evaluate the efficacy and safety of DCB-only approach in native coronary CTO. conditions: Coronary Artery Disease conditions: Total Occlusion of Coronary Artery studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Paclitaxel Drug-coated balloon measure: In-segment late lumen loss measure: Angiographic outcomes assessed directly post-PCI measure: HQ-IVUS outcomes assessed directly post-PCI measure: Physiologic outcomes assessed directly post-PCI measure: Angiographic outcomes at 6-months follow-up measure: HQ-IVUS outcomes at 6-months follow-up measure: Physiologic outcomes at 6-months follow-up measure: Computed tomographic outcomes at 12-months follow-up (CCTA substudy) measure: Clinical outcomes at 12-months follow-up sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Institute of Cardiology city: Warsaw state: Mazowieckie zip: 04-628 country: Poland name: Agnieszka Zdziennicka role: CONTACT email: [email protected] lat: 52.22977 lon: 21.01178 hasResults: False
|
<|newrecord|> nctId: NCT06275373 id: 20-10974 briefTitle: The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction acronym: Teprotumumab overallStatus: RECRUITING date: 2021-05-12 date: 2026-05-12 date: 2027-12-12 date: 2024-02-23 date: 2024-02-23 name: Walter Reed National Military Medical Center class: FED briefSummary: This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatment will be evaluated by an oculoplastic surgeon (Dr. Eva Chou) and endocrinologist (Dr. Thanh Hoang). conditions: Thyroid Eye Disease conditions: Graves Ophthalmopathy conditions: Graves Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 100 type: ESTIMATED name: Teprotumumab Injection [Tepezza] measure: Ophthalmological Clinical Activity Score (CAS) scoring measure: Thyroid stimulating immunoglobulin measure: HLA subtypes sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Walter Reed National Military Medical Center status: RECRUITING city: Bethesda state: Maryland zip: 20889 country: United States name: Thanh D Hoang, DO role: CONTACT phone: 301-295-5165 phoneExt: 6220 email: [email protected] name: Iris E Morris, PhD role: CONTACT phone: 3013194599 email: [email protected] lat: 38.98067 lon: -77.10026 hasResults: False
|
<|newrecord|> nctId: NCT06275360 id: SPLP-002-23F briefTitle: Repositioning Immunotherapy in VetArans With Lung Cancer acronym: RIVAL overallStatus: RECRUITING date: 2024-03-01 date: 2027-02-28 date: 2030-03-31 date: 2024-02-23 date: 2024-03-12 name: VA Office of Research and Development class: FED briefSummary: This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC. conditions: Non-Small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Carboplatin, paclitaxel, and nivolumab for three cycles followed by radiotherapy followed by nivolumab (for squamous cell lung cancer) OR Carboplatin, pemetrexed, and nivolumab for three cycles followed by radiotherapy followed by nivolumab (for lung adenocarcinoma) primaryPurpose: TREATMENT masking: NONE count: 25 type: ESTIMATED name: Nivolumab measure: Progression-free survival measure: Treatment Tolerance measure: Adverse Events measure: Best overall response rate (BOR) measure: Overall survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: VA Greater Los Angeles Healthcare System, West Los Angeles, CA status: NOT_YET_RECRUITING city: West Los Angeles state: California zip: 90073-1003 country: United States name: Daniel Shin, MD role: CONTACT phone: 310-478-3711 email: [email protected] name: Michelle Treadwell role: CONTACT phone: 3104783711 phoneExt: 45003 email: [email protected] lat: 34.0464 lon: -118.44813 facility: VA Connecticut Healthcare System West Haven Campus, West Haven, CT status: RECRUITING city: West Haven state: Connecticut zip: 06516-2770 country: United States name: Michal Rose, MD role: CONTACT phone: 203-932-5711 phoneExt: 2832 email: [email protected] name: Alicia Roy role: CONTACT phone: 2039325711 phoneExt: 3006 email: [email protected] lat: 41.27065 lon: -72.94705 facility: VA Ann Arbor Healthcare System, Ann Arbor, MI status: RECRUITING city: Ann Arbor state: Michigan zip: 48105-2303 country: United States name: Brittany M Pannecouk, BS role: CONTACT phone: 734-845-3966 email: [email protected] name: Laura A Randolph, BA role: CONTACT phone: (734) 845-5091 email: [email protected] name: Michael D Green role: PRINCIPAL_INVESTIGATOR name: Nithya Ramnath, MD role: PRINCIPAL_INVESTIGATOR lat: 42.27756 lon: -83.74088 facility: Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE status: NOT_YET_RECRUITING city: Omaha state: Nebraska zip: 68105-1850 country: United States name: Apar Kishor P Ganti, MD role: CONTACT phone: 402-346-8800 phoneExt: 3846 email: [email protected] name: Anna Kellogg role: CONTACT phone: 4029954143 email: [email protected] lat: 41.25626 lon: -95.94043 facility: Durham VA Medical Center, Durham, NC status: NOT_YET_RECRUITING city: Durham state: North Carolina zip: 27705-3875 country: United States name: Michael Kelley, MD role: CONTACT phone: 919-286-0411 phoneExt: 172199 email: [email protected] name: Maya Robinson role: CONTACT phone: 9192866926 email: [email protected] lat: 35.99403 lon: -78.89862 facility: Louis Stokes VA Medical Center, Cleveland, OH status: NOT_YET_RECRUITING city: Cleveland state: Ohio zip: 44106-1702 country: United States name: Charles Nock, MD role: CONTACT phone: 216-791-3800 phoneExt: 64825 email: [email protected] name: Margaret Titkin role: CONTACT phone: 2167913800 phoneExt: 36241 email: [email protected] lat: 41.4995 lon: -81.69541 facility: Hunter Holmes McGuire VA Medical Center, Richmond, VA status: NOT_YET_RECRUITING city: Richmond state: Virginia zip: 23249-0001 country: United States name: Bhaumik Patel, MD role: CONTACT phone: 804-675-5446 email: [email protected] lat: 37.55376 lon: -77.46026 hasResults: False
|
<|newrecord|> nctId: NCT06275347 id: 19CI 30 087 041 id: 1/1142021 type: OTHER domain: Comite del Centro de alta especialidad del Estado de Veracruz briefTitle: Very Low Calorie Ketogenic Low-fat Diet (VLCKLFD) acronym: Zelé2021 overallStatus: COMPLETED date: 2021-01-15 date: 2021-12-30 date: 2023-05-25 date: 2024-02-23 date: 2024-02-23 name: Universidad Veracruzana class: OTHER briefSummary: This study aimed to assess the efficacy and safety of the Zélé program, a controlled ketogenic diet, for weight loss and maintenance. It involved a randomized clinical trial with participants aged 18-60, BMI between 30-34.9 kg/m², and no severe health issues conditions: Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A Randomized Clinical Trial was conducted in patients with obesity type I patients primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Eligible patients were assigned to a one of the four VIME Weight Loss and Wellness Center for management and follow up according to their preference, a sequential number in inclusion order was given, with all the patients coded with a 4-digit number. This code was sent to the people in the food production plant where the patients were randomized in a double blinded study, with a 2:1 allocation for low-fat, normo-protein, controlled ketogenic diet (Zélé method) or low calories diet whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 88 type: ACTUAL name: Low-fat normoprotein Controlled Ketogenic Diet. name: Hypocaloric Balanced Diet measure: Evaluate the efficacy of this nutritional intervention measure: Volume of total body tissue corresponding to muscle measure: Percentage of body weight made up of adipose tissue measure: Visceral Fat measure: Bone mass measure: Total body water measure: Waist circumference measure: Hip circumference measure: Muscular strenght measure: Weight measure: Height measure: BMI Body index mass measure: Hemoglobin measure: Hematocrit measure: Leukocytes measure: Fasting Blood Glucose measure: Glycated hemoglobin (HbA1c) measure: Insulin measure: Creatinine measure: Urea measure: Uric acid measure: Sodium measure: Potassium measure: Calcium measure: Phosphorus measure: Magnesium measure: Albumin measure: Direct bilirubin measure: Indirect bilirubin measure: Total bilirubin measure: Alanine aminotransferase measure: Aspartate Amino Transferase measure: Total cholesterol measure: Triglycerides measure: High Density Lipoproteins measure: Low Density lipoproteins measure: Protein C Reactive measure: Thyroid stimulating hormone measure: Triiodothyronine measure: Thyroxine measure: Cholecalciferol measure: Gasometric variables, Partial pressure of oxygen (PaO2) measure: HCO3 (Bicarbonate ion plasma concentration) measure: Arterial pH measure: Lactic acid measure: Adherence to this nutritional intervention measure: Satisfaction survey sex: ALL minimumAge: 18 Years maximumAge: 61 Years stdAges: ADULT facility: Francisco J Nachón García city: Ciudad de Mexico country: Mexico lat: 19.42847 lon: -99.12766 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2021-04-23 uploadDate: 2024-02-16T19:37 filename: Prot_SAP_000.pdf size: 549651 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2021-04-23 uploadDate: 2024-01-14T23:04 filename: ICF_001.pdf size: 249137 hasResults: False
|
<|newrecord|> nctId: NCT06275334 id: 9133 briefTitle: Dinutuximab Beta at the HUS and the Toulouse Oncopole acronym: DNB overallStatus: RECRUITING date: 2023-11-28 date: 2024-11 date: 2024-11-28 date: 2024-02-23 date: 2024-02-23 name: University Hospital, Strasbourg, France class: OTHER briefSummary: In this study the investigators wish to describe the cohort of pediatric patients suffering from neuroblastoma and treated with Dinutuximab and to compare the costs and quality of life between the two French centers, the University Hospital of Strasbourg (HUS) and the Oncopole of Toulouse. conditions: Neuroblastoma studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 40 type: ESTIMATED measure: Comparison of two methods of treating a pediatric pathology in two French health establishments, the HUS and the Oncopole of Toulouse. sex: ALL minimumAge: 2 Years maximumAge: 25 Years stdAges: CHILD stdAges: ADULT facility: Service de Pharmacie - Stérilisation - CHU de Strasbourg - France status: RECRUITING city: Strasbourg zip: 67091 country: France name: Anne EL AATMANI, Pharm, PhD role: CONTACT phone: 33 3 88 12 78 06 email: [email protected] name: Emilie BERTHON, Pharm, PhD role: CONTACT phone: 33 3 88 12 78 06 email: [email protected] name: Anne EL AATMANI, Pharm, PhD role: PRINCIPAL_INVESTIGATOR name: Emilie BERTHON, PhamD, PhD role: PRINCIPAL_INVESTIGATOR name: Sophie PERRIAT, PhamD, PhD role: PRINCIPAL_INVESTIGATOR lat: 48.58392 lon: 7.74553 hasResults: False
|
<|newrecord|> nctId: NCT06275321 id: Elena Garcia Roca briefTitle: Physical Exercise Benefits for Cancer Patients overallStatus: RECRUITING date: 2021-11-05 date: 2024-07-27 date: 2025-07-30 date: 2024-02-23 date: 2024-02-23 name: Universitat Jaume I class: OTHER briefSummary: The purpose of the study was to analyze the effect of a synchronous-supervised online home-based group during a 6-month exercise program on physical fitness, body composition and adherence compared to an exercise recommendation group of patients undergoing breast cancer treatment without supervision. conditions: Cancer, Breast conditions: Sports Physical Therapy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: A prospective ramonized clinical trial with two groups primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 60 type: ESTIMATED name: Synchronous-supervised online home-based group name: Exercise recommendation group measure: Cardiorrespiratory fitness measure: Strength - Chair Stand (repetitions) measure: Flexibility measure: Incidence of treatments on quality of live assessed by EORTIC QLQ-C30 measure: Adherence measure: Rating of perceived exertion measure: Strength - Hand Grip (Kilograms) measure: Strength - Squat Jump (height in centimeters) sex: FEMALE minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Jaume I University status: RECRUITING city: Castellón De La Plana state: Castellón zip: 12071 country: Spain name: Elena Garcia Roca, MSc role: CONTACT phone: +34 629112367 email: [email protected] name: Eladio J Collado-Boira, PhD role: CONTACT phone: +34 606133368 email: [email protected] lat: 39.98567 lon: -0.04935 hasResults: False
|
<|newrecord|> nctId: NCT06275308 id: STUDY21100163 briefTitle: Effect of Raised End-Tidal pCo2 on Choroidal Volume overallStatus: RECRUITING date: 2023-02-27 date: 2025-02-27 date: 2025-02-27 date: 2024-02-23 date: 2024-02-23 name: University of Pittsburgh class: OTHER briefSummary: This study is to investigate the relationship between arterial carbon dioxide (CO2) concentration and vitreous pressure on the choroidal volume by integrated intraoperative OCT imaging under eye exams under anesthesia. conditions: Intraocular Pressure studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This is a descriptive case series. primaryPurpose: BASIC_SCIENCE masking: NONE count: 20 type: ESTIMATED name: Ventilation manipulation measure: Intraocular Pressure (IOP) (mmHg) measure: Choroidal thickness ( microns) sex: ALL maximumAge: 8 Years stdAges: CHILD facility: University of Pittsburgh Medical Center status: RECRUITING city: Pittsburgh state: Pennsylvania zip: 15224 country: United States name: Amy Monroe, MPH, MBA role: CONTACT email: [email protected] name: Kanwal Nischal, MD,FRCOphth role: PRINCIPAL_INVESTIGATOR name: Lieu Tran, MD role: SUB_INVESTIGATOR lat: 40.44062 lon: -79.99589 hasResults: False
|
<|newrecord|> nctId: NCT06275295 id: ZRJY2021-BJ08-03-01-01 briefTitle: A Retrospective Study of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis overallStatus: NOT_YET_RECRUITING date: 2024-03-20 date: 2024-12-24 date: 2024-12-31 date: 2024-02-23 date: 2024-02-23 name: China-Japan Friendship Hospital class: OTHER briefSummary: The goal of this observational study is to learn about the diagnostic effectiveness, safety, and influencing factors of transbronchial cryobiopsy（TBLC） in progressive pulmonary fibrosis. conditions: Pulmonary Fibrosis conditions: Transbronchial Cryobiopsy studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: RETROSPECTIVE count: 300 type: ESTIMATED measure: The diagnostic rate of MDD2 based on TBLC measure: The diagnostic rate of MDD1 sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06275282 id: HUM00235849 briefTitle: Regenerative Peripheral Nerve Interfaces for the Control of Above-knee Prostheses overallStatus: RECRUITING date: 2024-03-01 date: 2027-06-30 date: 2027-09-30 date: 2024-02-23 date: 2024-03-25 name: University of Michigan class: OTHER name: United States Department of Defense briefSummary: Individuals with an above-knee lower limb amputation are known to walk more slowly, expend more energy, have a greater risk of falling, and have reduced quality of life compared to individuals without amputation and those with below knee amputation. One of the driving factors behind these deficits is the lack of active function provided by above-knee prostheses with prosthetic knees and ankles. While many prosthetic devices have been developed for functional restoration after major lower extremity amputation, there remains no stable interface to facilitate reliable, long-term volitional control of an advanced robotic limb capable moving multiple joints. Moreover, there is no existing interface that provides useful sensory feedback that in turn enhances the functional capabilities of the prosthesis. To achieve both greater signal specificity and long-term signal stability, we have developed a biologic interface known as the Regenerative Peripheral Nerve Interface (RPNI). An RPNI consists of a peripheral nerve that is implanted into a free muscle graft that would otherwise go unused in the residual limb. As the nerve grows, it reinnervates the free muscle graft which undergoes a predictable sequence of revascularization and regeneration.
|
The main questions it aims to answer are:
|
1. Can the amplitude, movement specificity and stability of sciatic nerve RPNI electromyography (EMG) signals be detected up to one year post RPNI surgery?
|
2. Do RPNIs contain information to enable control of a physical motorized prosthetic leg with multiple degrees of freedom?
|
3. Does stimulation of sciatic nerve RPNIs provides meaningful sensory feedback?
|
Consenting participants with unilateral transfemoral amputation (TFA) will:
|
1. Undergo RPNI surgery and electrode implantation in the residual limb.
|
2. Attend regular follow-up visits following surgery to assess the health and signal strength of the RPNIs and their ability to use a prescribed prosthesis between 3- and 12-months following implantation.
|
3. Undergo explantation of electrodes following the conclusion of data collection. conditions: Amputation conditions: Prostheses and Implants studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 3 type: ESTIMATED name: Intramuscular electrodes measure: Intensity of pain in residual and phantom limbs measure: Neuropathic Pain in residual limb measure: Health-Related Quality of Life measure: Amplitude and signal-to-noise ratio for each RPNI measure: Classification accuracy for movements of the phantom limb measure: Threshold for sensation after electrical stimulation of RPNI sex: ALL minimumAge: 22 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Michigan status: RECRUITING city: Ann Arbor state: Michigan zip: 48109 country: United States name: Deanna Gates, PhD role: CONTACT phone: 723-647-2698 email: [email protected] name: Deanna Gates, PhD role: PRINCIPAL_INVESTIGATOR lat: 42.27756 lon: -83.74088 hasResults: False
|
<|newrecord|> nctId: NCT06275269 id: ZRJY2021-BJ08-04-02 briefTitle: Endoscopic Mucosal Injection Versus Ultrasound-Guided Injection of Triamcinolone to Treat Subglottic Stenosis overallStatus: NOT_YET_RECRUITING date: 2024-03-10 date: 2024-10-31 date: 2024-12-31 date: 2024-02-23 date: 2024-02-23 name: China-Japan Friendship Hospital class: OTHER briefSummary: This study employs a multicenter, randomized controlled trial method, where patients meeting the inclusion criteria for subglottic stenosis are randomly divided into two groups. These groups are respectively undergoing translaryngeal endoscopic mucosal injection and ultrasound-guided injection of triamcinolone treatment. The comparison will focus on various indicators such as therapeutic effect, incidence of adverse reactions, treatment costs, and hospital resource utilization between the two groups. The safety and effectiveness will be compared to determine the relative merits of the two treatment methods. conditions: Subglottic Stenosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Ultrasound-Guided name: Translaryngeal Endoscopic Mucosal Injection measure: Incidence of Short-Term Postoperative Complications measure: Overall medical expenses incurred by patients sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06275256 id: HS26226 briefTitle: Outcomes of MIST for BPH: A Single-Institution Prospective Study overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-03 date: 2025-03 date: 2024-02-23 date: 2024-02-23 name: University of Manitoba class: OTHER briefSummary: The investigators wish to perform a prospective study at the Men's Health Clinic in Winnipeg, Manitoba to accomplish two goals: 1) Prospectively describe 1 year outcomes for MIST therapies performed at the clinic 2) perform a head to head comparison of Rezum water vapor therapy vs the iTind device in respect to symptom score improvement, uroflow parameters and side effect profile. conditions: Benign Prostatic Hyperplasia studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Rezum name: iTind measure: Symptom Scores measure: Uroflow measure: Uroflow measure: Symptom Scores measure: Symptom Scores measure: Symptom Scores measure: Pain Scale sex: MALE minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Men's Health Clinic city: Winnipeg state: Manitoba zip: R3K 1M3 country: Canada name: Premal Patel, MD role: CONTACT phone: 204-221-4476 email: [email protected] name: Harliv Dhillon, BSc role: CONTACT phone: 2049904153 email: [email protected] lat: 49.8844 lon: -97.14704 hasResults: False
|
<|newrecord|> nctId: NCT06275243 id: ETICA-ULE-021-2022 briefTitle: Polymorphism of ApoE in Alzheimer's Disease: Genetic Study in Castile and Leon (Spain) overallStatus: ACTIVE_NOT_RECRUITING date: 2022-07-06 date: 2023-03-13 date: 2024-03-22 date: 2024-02-23 date: 2024-02-23 name: Universidad de León class: OTHER name: Consejo General de Colegios Oficiales de Enfermería España briefSummary: The general objective of this randomized and longitudinal clinical study was to estimate the frequencies of ApoE variants both in the user population of the "Messengers of Peace" Residences and the "Associations of Relatives of Alzheimer's Patients" in Castile y Leon, since, due to its geographical location at the crossroads, it has received multiple genetic contributions from both northern Europe, the Mediterranean area and northern Africa.
|
The main questions it aims to answer are:
|
* What are the allelic frequencies of ApoE variants in the population of individuals with Alzheimer's disease in Castile and Leon?
|
* Is there a correlation between the ApoE4 variant and the lipid profile in the blood of individuals with Alzheimer's disease in this region? conditions: Alzheimer Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: It is a longitudinal randomised clinical study, in which two study groups were used. A group of cases diagnosed with Alzheimer's disease and a control group of healthy individuals without Alzheimer's disease. primaryPurpose: DIAGNOSTIC masking: NONE count: 511 type: ACTUAL name: Kit Buccal swab collection & stabilization de Canvax® name: Cholesterol levels according to ApoE Genotype name: Assessing cardiovascular risk factors in all participants measure: Distribution of ApoE variants in the Alzheimer's disease population diagnosed in Castile and Leon. measure: Cardiovascular factors in individuals with Alzheimer's disease and healthy subjects. measure: ApoE genotypes and cholesterol levels in the Alzheimer's disease population diagnosed in Castile and Leon. sex: ALL minimumAge: 60 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of León city: León zip: 240071 country: Spain lat: 42.60003 lon: -5.57032 hasResults: False
|
<|newrecord|> nctId: NCT06275230 id: ZRJY2021-BJ08-02-07 briefTitle: Establishment of Human Lung Stem Cell Proliferation System and Organoid Construction in COPD overallStatus: NOT_YET_RECRUITING date: 2024-03-20 date: 2025-12-31 date: 2025-12-31 date: 2024-02-23 date: 2024-02-23 name: China-Japan Friendship Hospital class: OTHER briefSummary: The goal of this study is to proliferate human lung stem cell in vitro in order to establish a lung organoid derived from patients with COPD. The main question it aims to answer are:
|
* Can human lung stem cell proliferate in vitro.
|
* Can a lung organoid derived from patients with COPD be established. Participants will be sampled during pulmonary bronchoscope for organoid establishment. conditions: Chronic Obstructive Pulmonary Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 30 type: ESTIMATED measure: Number of Patients completed bronchoscope. sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
|
<|newrecord|> nctId: NCT06275217 id: HMRF17182481 briefTitle: Mindful Yoga for Postpartum Depression overallStatus: RECRUITING date: 2021-01-08 date: 2025-07-15 date: 2025-12-31 date: 2024-02-23 date: 2024-02-23 name: The Hong Kong Polytechnic University class: OTHER briefSummary: This is a parallel-group randomized controlled trial. A total of 198 postpartum women with depressive symptoms (EPDS scores≥8 at baseline) will be recruited and randomized into two groups: 10-week mindful yoga intervention and 10-week psychoeducation program. Clinical assessment of depression, self-report questionnaires and salivary cortisol tests will be performed at baseline, after 10-week intervention, and at 6-month and 12-month follow-ups. The investigators expected that the mindful yoga intervention will reduce depression after 10 weeks compared to psychoeducation. The mindful yoga intervention will further reduce anxiety, stress, improve quality of life and sleep, and steepen diurnal cortisol slopes. These effects will be maintained for at least six months. conditions: Mood Disorders studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 198 type: ESTIMATED name: Mindfulness-based yoga program name: Psychoeducation measure: Edinburgh Postnatal Depression Scale measure: Depression Anxiety Stress Scale-Depression measure: Depression Anxiety Stress Scale-Anxiety measure: Depression Anxiety Stress Scale-Stress measure: Pittsburgh Sleep Quality Index measure: 36 Item-Short Form Health Survey Questionnaire measure: Five Facet Mindfulness Questionnaire measure: Pregnancy Symptom Inventory measure: Cortisol concentration level measure: Physical fitness measure: Balance sex: FEMALE minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: The Hong Kong Polytechnic University status: RECRUITING city: Hong Kong country: Hong Kong name: Jessie JX Lin, PhD role: CONTACT email: [email protected] lat: 22.27832 lon: 114.17469 hasResults: False
|
<|newrecord|> nctId: NCT06275204 id: 101101252 id: 101101252 type: OTHER_GRANT domain: EU4H-2022-PJ-01 briefTitle: H. Pylori Screen-and-treat Study in a Population of Young Adults overallStatus: RECRUITING date: 2024-03-04 date: 2026-10-01 date: 2026-12-01 date: 2024-02-23 date: 2024-03-05 name: University of Latvia class: OTHER name: Clinical Hospital Center Rijeka name: Clinical Hospital Centre Zagreb name: Beacon Hospital name: Wroclaw Medical University name: Iuliu Hatieganu University of Medicine and Pharmacy name: National Institute of Public Health, Slovenia briefSummary: Gastric cancer remains a major challenge to public health on a global scale. H. pylori related cancer burden contributes to the largest proportion of cancer cases attributable to infections in Europe. Considering its absolute burden and persisting disparities, in addition to the substantial prevalence of H. pylori infection worldwide that is treatable, gastric cancer is a logical target for urgent action for prevention. Population-based H. pylori test-and-treat has therefore been proposed as a strategy for gastric cancer prevention. To fill the gaps in knowledge about gastric cancer prevention through H. pylori screening and eradication in younger adults, a study of a population-based H. pylori test-and-treat strategy in Ireland, Croatia, Latvia, Poland, Romania and Slovenia.
|
Main goals of this study are to assess future program processes, feasibility, acceptability and effectiveness. In total of 6,800 adults aged 30-34 will be tested for H. pylori infection. They will be randomly selected to represent the chosen population and invited to participate in the study based on informed consent. Confirmed infections will be treated by available combined therapy in line with treatment guidelines and the success of eradication will be retested during a control check-up.
|
Patients who will provide their consent to participate will undertake an interview about the risk factors in early childhood and their habits regarding alcohol consumption and use of tobacco. Compliance to testing and treatment, treatment results, adverse effects and reasons for dropping out will be additionally monitored. Gathered data will be analysed in alignment with our research questions. The investigators will disseminate reports and present the results to both the general public and the scientific community in order to foster future developments in gastric cancer prevention. conditions: Gastric Cancer conditions: H Pylori Infection conditions: H Pylori Eradication conditions: H-pylori studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 6800 type: ESTIMATED name: Bismuth-based quadruple therapy name: Levofloxacin-based quadruple therapy name: Standard triple therapy name: Levofloxacin-based triple measure: Healthcare workers' assessment of feasibility and acceptability of the proposed practical implementation of a screening program measure: Eradication rate of infection with H. pylori measure: Description of the adverse events profile measure: Participation rate of subjects selected for the program sex: ALL minimumAge: 30 Years maximumAge: 34 Years stdAges: ADULT facility: University Hospital Centre Zagreb status: RECRUITING city: Zagreb state: Grad Zagreb zip: 10000 country: Croatia name: Masa Cavlina Sevo, MD role: CONTACT phone: 00385995900847 email: [email protected] name: Mirjana Kalauz, Asst. Prof. role: CONTACT phone: 0038598519088 email: [email protected] name: Mirjana Kalauz, Asst. Prof. role: PRINCIPAL_INVESTIGATOR name: Pave Markos, MD, PhD role: SUB_INVESTIGATOR name: Tihomir Bradic, MD role: SUB_INVESTIGATOR name: Masa Cavlina Sevo, MD role: SUB_INVESTIGATOR lat: 45.81444 lon: 15.97798 facility: Clinical Hospital Center Rijeka status: RECRUITING city: Rijeka zip: 51000 country: Croatia name: Sandra Milic, MD role: CONTACT phone: 0038551658122 email: [email protected] lat: 45.32674 lon: 14.44239 facility: Beacon Hospital status: RECRUITING city: Dublin zip: D18 AK68 country: Ireland name: Charlene Deane, MB Bch BAO, MSc role: CONTACT phone: 00353879114305 email: [email protected] name: Ruth Pilkington, MB BcH BAO role: CONTACT phone: 0035312937521 email: [email protected] name: Colm O Morain, MD, MB BcH BAO, FRCPI role: PRINCIPAL_INVESTIGATOR name: Orlaith Kelly, PHD, MB BcH role: SUB_INVESTIGATOR name: Charlene Deane, MB Bch BAO, MSc, MRCP role: SUB_INVESTIGATOR lat: 53.33306 lon: -6.24889 facility: Clinical and Preventive Medicine of the University of Latvia status: NOT_YET_RECRUITING city: Riga zip: LV1079 country: Latvia name: Marcis Leja, MD, PhD role: CONTACT phone: 371+29497500 email: [email protected] name: Marcis Leja, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Danute Razuka Ebela, MD, PhD role: SUB_INVESTIGATOR name: Linda Mezmale, MD role: SUB_INVESTIGATOR lat: 56.946 lon: 24.10589 facility: Wroclaw Medical University status: RECRUITING city: Wroclaw zip: 50-367 country: Poland name: Katarzyna Malinowska role: CONTACT phone: 00487178417 99 email: [email protected] name: Elzbieta Olejnik role: CONTACT phone: 00717841666 email: [email protected] name: Katarzyna Neubauer, MD, PhD, Assoc. Prof. role: PRINCIPAL_INVESTIGATOR name: Radoslaw Kempinski, MD, PhD role: SUB_INVESTIGATOR lat: 51.1 lon: 17.03333 facility: Iuliu Hatieganu University of Medicine and Pharmacy status: RECRUITING city: Cluj-Napoca state: Cluj County zip: 400003 country: Romania name: Dan Lucian Dumitrascu, Prof role: CONTACT phone: 0040722756475 email: [email protected] name: Radu Farcas, MD, PhD student role: CONTACT phone: 0040757554422 email: [email protected] name: Radu Farcas, MD, PhD student role: SUB_INVESTIGATOR lat: 46.76667 lon: 23.6 facility: National Institute of Public Health, Slovenia status: RECRUITING city: Ljubljana zip: 1000 country: Slovenia name: Mitja Oblak, MSc role: CONTACT phone: 0038612441541 email: [email protected] name: Tatjana Kofol, MD role: CONTACT phone: 0038612441484 email: [email protected] name: Bojan Tepeš, prof., MD role: PRINCIPAL_INVESTIGATOR lat: 46.05108 lon: 14.50513 hasResults: False
|
<|newrecord|> nctId: NCT06275191 id: 80758 id: 1UG3DE032621-01 type: NIH link: https://reporter.nih.gov/quickSearch/1UG3DE032621-01 id: 4UH3DE032621-02 type: NIH link: https://reporter.nih.gov/quickSearch/4UH3DE032621-02 briefTitle: Alternatives to Dental Opioid Prescribing After Tooth Extraction acronym: ADOPT overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2028-01 date: 2028-12 date: 2024-02-23 date: 2024-03-06 name: Douglas Oyler class: OTHER name: National Institute of Dental and Craniofacial Research (NIDCR) briefSummary: The goal of this clinical trial is to test a three-item intervention in oral surgeons who remove teeth. The main questions it aims to answer are:
|
* Can the intervention reduce opioid prescriptions to adolescents and young adults after tooth removal?
|
* Do oral surgeons' beliefs about the intervention and opioid prescribing change?
|
* Do patients that report using opioids after tooth removal have different experiences than patients that do not?
|
Oral surgeon participants will:
|
* Attend a 1-hour education session with a trained pharmacist
|
* Receive patient instructions and blister packs of pain medicine to give to patients
|
* Complete 2 surveys about feasibility and appropriateness
|
Patient participants will complete a survey about pain and medication use after having a tooth removed.
|
Researchers will compare the intervention to usual care to see if it reduces opioid prescribing. conditions: Analgesics, Opioid conditions: Acute Pain conditions: Tooth Extraction conditions: Adolescent conditions: Acetaminophen conditions: Ibuprofen studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: Stepped wedge cluster randomized trial primaryPurpose: OTHER masking: DOUBLE maskingDescription: Blinding to the intervention is not possible in this study, as the intervention requires provider engagement. Provider participants and any clinic personnel will be blinded to the allocation sequence, and those not yet receiving the intervention will not be aware of the time at which they will have the intervention implemented. The study biostatistician will be aware of the allocation sequence.
|
At the beginning of each period, the study biostatistician will inform the research coordinator, project manager, academic detailing pharmacist, and PIs which cluster will be transitioning to the intervention condition next. This information will be used to facilitate scheduling academic detailing visits and coordinate blister pack and patient instructions material assembly. The clinic will be informed of their allocation during Visit 4 to facilitate scheduling academic detailing visits. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 38159 type: ESTIMATED name: Multicomponent intervention name: Usual care measure: Odds of post-extraction opioid prescription to adolescent/young adults after tooth extraction measure: (Change in) intervention feasibility measure: (Change in) intervention appropriateness measure: (Change in) opioid prescribing feasibility measure: (Change in) opioid prescribing appropriateness measure: Self-reported pain measure: Self-reported pain interference measure: Self-reported pain satisfaction sex: ALL minimumAge: 12 Years maximumAge: 25 Years stdAges: CHILD stdAges: ADULT facility: University of Kentucky city: Lexington state: Kentucky zip: 40536 country: United States name: Jennifer Dolly Prothro, MPH role: CONTACT email: [email protected] name: Enif Dominguez, DDS role: SUB_INVESTIGATOR name: Patricia R Freeman, PhD role: SUB_INVESTIGATOR name: Hannah K Knudsen, PhD role: SUB_INVESTIGATOR name: Craig S Miller, DDS role: SUB_INVESTIGATOR name: Sharon L Walsh, PhD role: SUB_INVESTIGATOR name: Philip M Westgate, PhD role: SUB_INVESTIGATOR lat: 37.98869 lon: -84.47772 hasResults: False
|
<|newrecord|> nctId: NCT06275178 id: ZRJY2021-BJ08-02-04 briefTitle: Medical Thoracoscopy for Diagnosing Unexplained Pleural Effusion: a National Multicenter Retrospective Study overallStatus: NOT_YET_RECRUITING date: 2024-03-20 date: 2024-12-24 date: 2024-12-31 date: 2024-02-23 date: 2024-02-23 name: China-Japan Friendship Hospital class: OTHER briefSummary: This study is a national multicenter retrospective study. Patients with unexplained pleural effusion who underwent thoracoscopic or video-assisted thoracoscopic biopsy for patients in recent 10 years were retrospectively collected from multiple centers to understand the proportion and final etiological composition of pleural effusion in China. conditions: Pleural Effusion conditions: Pleural Effusion, Malignant conditions: Fibrinous Pleuritis studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 5000 type: ESTIMATED name: Medical thoracoscopy measure: The proportion of fibrinous pleurisy in Chinese population sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06275165 id: 202301754B0 briefTitle: The Effects of Acupressure on Improving Postoperative Gastrointestinal Symptom Distress in Esophageal Cancer Patients overallStatus: RECRUITING date: 2024-03-27 date: 2025-07-18 date: 2025-07-18 date: 2024-02-23 date: 2024-03-29 name: CHEN, CHIA-CHEN class: OTHER briefSummary: This study is a quasi-experimental design clinical trial with the primary objective of comparing the health status of patients with esophageal cancer. Participants were divided into an experimental group and a control group. Patients in the experimental group received routine care and acupressure for 5 consecutive days starting from the day after entering the ward after esophageal cancer surgery, in the control group, participants received routine care, and Participants were assessed on the Gastrointestinal Symptom Distress Scale at the end of the intervention. The aim of this study was to verify the effectiveness of acupressure in improving of gastrointestinal symptoms distress after esophageal cancer surgery. conditions: Esophageal Cancer conditions: Gastrointestinal Dysfunction studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants were divided into an experimental group and a control group. experimental group: received acupressure for 5 days in addition to regular care.
|
control group: received regular postoperative care. primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: acupressure measure: Change from Baseline in gastrointestinal symptom distress Scale at study day 5(end day) sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chang Gung Memotial Hospital status: RECRUITING city: Taoyuan country: Taiwan name: Chia-Chen Chen role: CONTACT phone: +886-3-3281200 phoneExt: 3005 email: [email protected] lat: 24.95233 lon: 121.20193 hasResults: False
|
<|newrecord|> nctId: NCT06275152 id: HDRIC-01 briefTitle: The Protective Effect of Remote Ischemic Conditioning on Residual Renal Function in Hemodialysis Patients (RIC-HD) acronym: RIC-HD overallStatus: ENROLLING_BY_INVITATION date: 2024-02-20 date: 2026-01-19 date: 2026-01-19 date: 2024-02-23 date: 2024-02-26 name: Yuanjun Yang class: OTHER briefSummary: Hemodialysis (HD) is the main renal replacement therapy for patients with end-stage renal disease. However, factors such as hemodynamic instability can lead to gradual loss of residual renal function (RRF) in HD patients. The loss of RRF not only affects the adequacy of dialysis and complications control but also impacts the patients' quality of life and survival. Unfortunately, there are currently no effective methods to protect RRF. The purpose of this study is to validate the protective effect of remote ischemic conditioning (RIC) on RRF in HD patients. This will provide evidence for the application of RIC in protecting RRF in HD patients. conditions: End-stage Renal Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: randomized controlled pilot study primaryPurpose: PREVENTION masking: QUADRUPLE maskingDescription: Only Research Assistant will be unblinded. Participant, clinical team, PI, etc. will all be blinded to the randomization group. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Remote ischemic conditioning name: Sham Remote Ischemic Conditioning measure: time to anuria measure: residual renal function (RRF) measure: Change in the renal cerebral oxygen saturation measure: serum creatinine measure: serum urea nitrogen measure: C-reactive protein (CRP) measure: Interleukin-6 measure: TFF3 measure: KIM-1 measure: IP-10 measure: hemoglobin measure: systolic pressure measure: diastolic pressure sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chinese PLA General Hospital city: Beijing state: Beijing zip: 100853 country: China lat: 39.9075 lon: 116.39723 hasResults: False
|
<|newrecord|> nctId: NCT06275139 id: 2023-GSP-GG-9 briefTitle: Integrated Assessment of Cervicocerebral Vessels to Improve the Brain Injury for CAGB Patients (IACV Study) overallStatus: RECRUITING date: 2023-01-01 date: 2024-06-30 date: 2024-12-31 date: 2024-02-23 date: 2024-02-23 name: China National Center for Cardiovascular Diseases class: OTHER_GOV briefSummary: The goal of this study is to establish a prospective study to focus on the high-risk stroke population who require coronary artery bypass graft surgery. It will divide the eligible patients into 1:1 group by simple randomization method. The control group adopt the traditional diagnosis and treatment mode, and only head CT plain scan and carotid artery ultrasound shall be performed. If necessary, relevant disciplines would be consulted but no integrated assessment of cervicocerebral vessels be arranged. The final treatment plan would be decided by the surgeon alone. The experimental group adopt the multidisciplinary collaboration and integrated evaluation mode. In addition to routine diagnosis and treatment as above-mentioned, integrated assessment of cervicocerebral vessels shall be performed, including transcranial color-coded doppler, cerebral perfusion with multislice CT, and cognitive function assessment. Based on the above results, surgical plans will be formulated jointly by multiple disciplines including neurologists, vascular surgeons, ICU physicians and cardiac surgeons. Researchers will compare the two groups to investigate whether integrated assessment of cervicocerebral vessels can reduce the incidence of brain injury compared with conventional diagnosis and treatment mode. conditions: Coronary Disease conditions: Coronary Artery Bypass conditions: Strokes Thrombotic studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Integrated assessment of cervicocerebral vessels shall be performed, including transcranial color-coded doppler, cerebral perfusion with multislice CT, and cognitive function assessment. primaryPurpose: PREVENTION masking: NONE count: 348 type: ESTIMATED name: Integrated Assessment of Cervicocerebral Vessels measure: The incidence of neurological complications measure: The incidence of major adverse cardiac events measure: Neurological scale scores sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fuwai Hospital; National Cardiovascular Center; Peking Union Medical College & Chinese Academy of Medical Sciences status: RECRUITING city: Beijing state: Beijing zip: 100037 country: China name: Huanmei Liu, MD role: CONTACT email: [email protected] lat: 39.9075 lon: 116.39723 hasResults: False
|
<|newrecord|> nctId: NCT06275126 id: 23-08026433 id: R01CA256877-01A1 type: NIH link: https://reporter.nih.gov/quickSearch/R01CA256877-01A1 briefTitle: Optimizing Surgical Decisions in Young Adults With Breast Cancer acronym: CONSYDER overallStatus: RECRUITING date: 2024-03-13 date: 2026-09 date: 2027-05 date: 2024-02-23 date: 2024-04-10 name: Weill Medical College of Cornell University class: OTHER name: National Institutes of Health (NIH) name: National Cancer Institute (NCI) briefSummary: The goal of this study is to understand and improve the breast surgical decision-making process for young women newly diagnosed with breast cancer. As part of this study, the investigators will evaluate the impact and use a web-based tool called CONSYDER that is designed to provide useful information to young breast cancer patients. It is also meant to improve communication between young women and their surgeons with the purpose of helping patients make appropriate surgical decisions.
|
Participants will complete surveys within 1 week of the surgical consult and 6 months after surgery. Patients who receive neoadjuvant chemotherapy will also be surveyed after the completion of neoadjuvant treatment but prior to surgery. Some patients will be invited for an interview after their surgery as part of the evaluation. A subset of patients/surgeons will also have their surgical consultation audio-recorded. conditions: Breast Cancer Stage 0 conditions: Breast Cancer Stage I conditions: Breast Cancer Stage II conditions: Breast Cancer Stage III studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: The study is a pragmatic, Type II hybrid effectiveness-implementation, stepped-wedge design that will incorporate a mixed-methods approach to test the efficacy and evaluate the implementation of the CONSYDER intervention primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 800 type: ESTIMATED name: CONSYDER decision aid measure: Pre-surgical decisional conflict as measured by the Decisional Conflict Scale (DCS) measure: Use of CONSYDER pre-consult measure: Knowledge as measured by adapted Breast Cancer Surgery Decision Quality Instrument (BCS -DQI) measure: Treatment goals and preferences as measured by adapted Breast Cancer Surgery Decision Quality Instrument (BCS-DQI) measure: Anxiety, as measured with the 8-item Patient Reported Outcomes Measurement Information System (PROMIS) - Anxiety - Short Form measure: Self-efficacy in communication as measured by the Perceived Efficacy in Patient-Physician Interactions scale (PEPPI). measure: Decisional regret as measured by the Decision Regret Scale (DRS) measure: Receipt of contralateral prophylactic mastectomy measure: Fidelity of implementation of CONSYDER via patient portal email measure: Use of CONSYDER post-consult measure: Frequency of CONSYDER use pre-consult measure: Frequency of CONSYDER use post-consult sex: FEMALE minimumAge: 18 Years maximumAge: 44 Years stdAges: ADULT facility: Yale Cancer Center status: RECRUITING city: New Haven state: Connecticut zip: 06510 country: United States name: Rachel Greenup, MD, MPH role: CONTACT phone: 203-737-2966 email: [email protected] name: Rachel Greenup, MD, MPH role: PRINCIPAL_INVESTIGATOR lat: 41.30815 lon: -72.92816 facility: Dana-Farber Cancer Institute status: RECRUITING city: Boston state: Massachusetts zip: 02215 country: United States name: Ann Partridge, MD, MPH role: CONTACT phone: 617-632-3800 email: [email protected] name: Ann Partridge, MD, MPH role: PRINCIPAL_INVESTIGATOR lat: 42.35843 lon: -71.05977 facility: Weill Cornell Medicine status: RECRUITING city: New York state: New York zip: 10065 country: United States name: Shoshana Rosenberg, ScD, MPH role: CONTACT phone: 646-962-8041 email: [email protected] name: Darima Dorzhieva role: CONTACT phone: 646-962-8666 email: [email protected] name: Shoshana Rosenberg, ScD, MPH role: PRINCIPAL_INVESTIGATOR lat: 40.71427 lon: -74.00597 facility: Duke Cancer Institute status: RECRUITING city: Durham state: North Carolina zip: 27710 country: United States name: Jennifer Plichta, MD, MS role: CONTACT phone: 919-681-9156 email: [email protected] name: Jennifer Plichta, MD, MS role: PRINCIPAL_INVESTIGATOR lat: 35.99403 lon: -78.89862 hasResults: False
|
<|newrecord|> nctId: NCT06275113 id: K25 briefTitle: BRING-UP Prevention overallStatus: RECRUITING date: 2023-09-15 date: 2026-06-30 date: 2026-06-30 date: 2024-02-23 date: 2024-02-23 name: Heart Care Foundation class: OTHER briefSummary: The aim of this observational study is to assess in patients with a documented athero-thrombotic event: coronary artery disease (CAD), cerebrovascular disease (CVD), peripheral artery disease (PAD):
|
* the level of adherence to guideline recommendations with the assumption to improve the rate of patients at goal for cholesterol levels.
|
* the level of adherence to guideline recommendations and the rate of patients at goal for the other relevant and modifiable risk factors for cardiovascular event recurrence. conditions: Ischemic Heart Disease conditions: Cerebrovascular Disorders conditions: Peripheral Arterial Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 6000 type: ESTIMATED measure: Adherence to guideline for cholesterol level measure: Adherence to guideline for other risk factors measure: Patients' outcome sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ospedale Barone Lombardo - Cardiologia E Utic status: NOT_YET_RECRUITING city: Canicatti' state: AG zip: 92024 country: Italy name: LUCIANO SUTERA SARDO, MD role: CONTACT lat: 37.35842 lon: 13.84786 facility: Ospedale San Giacomo D'Altopasso - Uoc Cardiologia status: RECRUITING city: Licata state: AG zip: 92027 country: Italy name: SALVATORE MONTALTO, MD role: CONTACT lat: 37.10267 lon: 13.93972 facility: Ospedale Santo Spirito - Sc Cardiologia status: RECRUITING city: Casale Monferrato state: AL zip: 15033 country: Italy name: FEDERICO NARDI, MD role: CONTACT lat: 45.13338 lon: 8.4525 facility: Ospedale San Giacomo - Sc Cardiologia status: RECRUITING city: Novi Ligure state: AL zip: 15067 country: Italy name: MARIA E ROVERE, MD role: CONTACT lat: 44.76246 lon: 8.787 facility: Ospedali Riuniti - Clinica Di Cardiologia E Aritmologia status: NOT_YET_RECRUITING city: Ancona state: AN zip: 60122 country: Italy name: PAOLO COMPAGNUCCI, MD role: CONTACT lat: 43.5942 lon: 13.50337 facility: Ospedali Riuniti - Sod Cardiologia Ospedaliera E Utic status: NOT_YET_RECRUITING city: Ancona state: AN zip: 60122 country: Italy name: GIAN PIERO PERNA, MD role: CONTACT lat: 43.5942 lon: 13.50337 facility: Casa Di Cura Villa Serena - U.O. Cardiologia Riabilitativa status: RECRUITING city: Jesi state: AN zip: 60035 country: Italy name: NICOLA RUSSO, MD role: CONTACT lat: 43.52142 lon: 13.24368 facility: Ospedale Madonna Del Soccorso - Uoc Cardiologia Indirizzo Riabilitativo status: RECRUITING city: San Benedetto Del Tronto state: AP zip: 63074 country: Italy name: MICHELA MOLISANA, MD role: CONTACT lat: 42.9568 lon: 13.87676 facility: Ospedale San Donato - U.O.C Cardiologia status: RECRUITING city: Arezzo state: AR zip: 52100 country: Italy name: MATTEO ROCCO RECCIA, MD role: CONTACT lat: 43.46276 lon: 11.88068 facility: Ospedale Valdichiana Santa Margherita - Uosd Cardiologia S.O. Cortona status: RECRUITING city: Cortona state: AR zip: 52044 country: Italy name: SIMONA D'ORAZIO, MD role: CONTACT lat: 43.27467 lon: 11.98533 facility: Aorn San Giuseppe Moscati - U.O. Cardiologia/Utic 'D. Rotiroti' status: RECRUITING city: Avellino state: AV zip: 83100 country: Italy name: EMILIO DI LORENZO, MD role: CONTACT lat: 40.91494 lon: 14.79103 facility: Ospedale Miulli - U.O.C. Cardiologia - Utic status: RECRUITING city: Acquaviva Delle Fonti state: BA zip: 70021 country: Italy name: NICOLA VITULANO, MD role: CONTACT lat: 40.89704 lon: 16.8433 facility: Ospedale Della Murgia - Fabio Perinei - S.C. Cardiologia-Utic status: RECRUITING city: Altamura state: BA zip: 70022 country: Italy name: PIETRO SCICCHITANO, MD role: CONTACT lat: 40.82664 lon: 16.54952 facility: Ospedale San Paolo - Cardiologia-Utic status: RECRUITING city: Bari state: BA zip: 70123 country: Italy name: PASQUALE CALDAROLA, MD role: CONTACT lat: 41.11148 lon: 16.8554 facility: Ics Maugeri Spa Societa' Benefit Irccs Bari - Cardiologia Riabilitativa status: RECRUITING city: Bari state: BA zip: 70124 country: Italy name: ANDREA PASSANTINO, MD role: CONTACT lat: 41.11148 lon: 16.8554 facility: Mater Dei Hospital - Riabilitazione Cardiologica status: RECRUITING city: Bari state: BA zip: 70124 country: Italy name: ROCCO LAGIOIA, MD role: CONTACT lat: 41.11148 lon: 16.8554 facility: Ospedale Umberto I - U.O.C. Cardiologia status: RECRUITING city: Corato state: BA zip: 70033 country: Italy name: ILARIA L NALIN, MD role: CONTACT lat: 41.15171 lon: 16.41143 facility: Ospedale San Giacomo - Uoc Cardiologia status: RECRUITING city: Monopoli state: BA zip: 70043 country: Italy name: ONOFRIO ROSSI, MD role: CONTACT lat: 40.94918 lon: 17.29717 facility: Ospedale Degli Infermi - Sc Di Cardiologia status: RECRUITING city: Ponderano state: BI zip: 13875 country: Italy name: ANDREA ROGNONI, MD role: CONTACT lat: 45.53846 lon: 8.05592 facility: Presidio Ospedaliero "Santa Maria Del Prato" - U.O.C. Di Cardiologia-Utic status: RECRUITING city: Feltre state: BL zip: 32032 country: Italy name: CHRISTIAN PIERGENTILI, MD role: CONTACT lat: 46.02085 lon: 11.90031 facility: Ospedale Di Bentivoglio - U.O. Cardiologia Pianura status: RECRUITING city: Bentivoglio state: BO zip: 40010 country: Italy name: GIANFRANCO TORTORICI, MD role: CONTACT lat: 44.6369 lon: 11.41737 facility: Ospedale Maggiore - U.O.C. Di Cardiologia status: RECRUITING city: Bologna state: BO zip: 40133 country: Italy name: GIANMARCO IANNOPOLLO, MD role: CONTACT lat: 44.49381 lon: 11.33875 facility: Ospedale Bellaria - U.O. Di Cardiologia status: RECRUITING city: Bologna state: BO zip: 40139 country: Italy name: STEFANO URBINATI, MD role: CONTACT lat: 44.49381 lon: 11.33875 facility: Ospedale Perrino - U.O.C. Di Cardiologia status: RECRUITING city: Brindisi state: BR zip: 72100 country: Italy name: GIAN PAOLO GIORDA, MD role: CONTACT lat: 40.63215 lon: 17.93607 facility: Casa Di Cura San Camillo - U.O. Cardiologia status: RECRUITING city: Brescia state: BS zip: 25123 country: Italy name: MARCO CAPRETTI, MD role: CONTACT lat: 45.53558 lon: 10.21472 facility: Ospedale Di Desenzano Del Garda - Divisione Di Cardiologia - U.C.C. status: RECRUITING city: Desenzano Del Garda state: BS zip: 25015 country: Italy name: GIOSUE' MASCIOLI, MD role: CONTACT lat: 45.47127 lon: 10.53559 facility: Ospedale Civile 'La Memoria' - U.O. Di Cardiologia status: RECRUITING city: Gavardo state: BS zip: 25085 country: Italy name: MARCO TRIGGIANI, MD role: CONTACT lat: 45.58939 lon: 10.44257 facility: Istituti Clinici Scientifici Maugeri Irccs Sede Di Lumezzane - U.O. Di Cardiologia Riabilitativa status: RECRUITING city: Lumezzane state: BS zip: 25065 country: Italy name: FRANCESCA RIVADOSSI, MD role: CONTACT lat: 45.64789 lon: 10.26487 facility: Ospedale Monsignor Angelo R. Di Miccoli - Uoc Cardiologia/Utic status: NOT_YET_RECRUITING city: Barletta state: BT zip: 76121 country: Italy name: FRANCESCO BARTOLOMUCCI, MD role: CONTACT lat: 41.31429 lon: 16.28165 facility: Ospedale Centrale Bolzano - Cardiologia E Prove Funzionali status: RECRUITING city: Bolzano state: BZ zip: 39100 country: Italy name: PRISCILLA MILEWSKI, MD role: CONTACT lat: 46.49067 lon: 11.33982 facility: Arnas G. Brotzu - Cardiologia Con Utic status: NOT_YET_RECRUITING city: Cagliari state: CA zip: 09134 country: Italy name: MARCO CORDA, MD role: CONTACT lat: 39.23054 lon: 9.11917 facility: Arnas G. Brotzu - S.S.D. Cardioriabilitazione status: RECRUITING city: Cagliari state: CA zip: 09134 country: Italy name: ANDREA BIANCO, MD role: CONTACT lat: 39.23054 lon: 9.11917 facility: A.O.U. Cagliari Policlinico Monserrato - Sc Cardiologia Utic Emodinamica status: NOT_YET_RECRUITING city: Monserrato state: CA zip: 09124 country: Italy name: ROBERTA MONTISCI, MD role: CONTACT lat: 39.25642 lon: 9.1444 facility: Azienda Ospedaliera S. Anna E S. Sebastiano - U.O. Cardiologia D'Emergenza Con Utic status: RECRUITING city: Caserta state: CE zip: 81100 country: Italy name: PAOLO CALABRO', MD role: CONTACT lat: 41.07262 lon: 14.33231 facility: Villa Delle Magnolie - Riabilitazione Cardiologica status: RECRUITING city: Castel Morrone state: CE zip: 81020 country: Italy name: FRANCESO PERONE, MD role: CONTACT lat: 41.12102 lon: 14.35473 facility: Casa Di Cura San Michele - Uo Cardiologia status: RECRUITING city: Maddaloni state: CE zip: 81024 country: Italy name: MARCO PEPE, MD role: CONTACT lat: 41.03578 lon: 14.3823 facility: Ospedale San Giuseppe E Melorio - U.O.C. Cardiologia Utic status: RECRUITING city: Santa Maria Capua Vetere state: CE zip: 81055 country: Italy name: PIETRO IODICE, MD role: CONTACT lat: 41.08156 lon: 14.25342 facility: Ospedale Policlinico Ss. Annunziata - Uoc Cardiologia-Utic status: NOT_YET_RECRUITING city: Chieti state: CH zip: 66013 country: Italy name: MARCO ZIMARINO, MD role: CONTACT lat: 42.34827 lon: 14.16494 facility: Santa Barbara Hospital - Cardiologia status: RECRUITING city: Gela state: CL zip: 93012 country: Italy name: GIUSEPPE LA ROSA, MD role: CONTACT lat: 37.07381 lon: 14.24038 facility: Azienda Ospedaliera Santa Croce E Carle - Sc Cardiologia status: RECRUITING city: Cuneo state: CN zip: 12100 country: Italy name: FRANCESCA GIORDANA, MD role: CONTACT lat: 44.39071 lon: 7.54828 facility: Ospedale Regina Montis Regalis - U.O. Cardiologia-Utic status: RECRUITING city: Mondovì state: CN zip: 12084 country: Italy name: MAURO FEOLA, MD role: CONTACT lat: 44.39603 lon: 7.81764 facility: Ospedale Maggiore Ss. Annunziata - Sc Cardiologia status: RECRUITING city: Savigliano state: CN zip: 12038 country: Italy name: MICHELE DE BENEDICTIS, MD role: CONTACT lat: 44.64808 lon: 7.65677 facility: Ospedale Oglio Po - U.O. Di Cardiologia-Utic status: RECRUITING city: Casalmaggiore state: CR zip: 26041 country: Italy name: CARLO PISCICELLI, MD role: CONTACT lat: 44.98981 lon: 10.42055 facility: Ospedale Annunziata - Uoc Cardiologia Interventistica status: RECRUITING city: Cosenza state: CS zip: 87100 country: Italy name: FRANCESCO GRECO, MD role: CONTACT lat: 39.2989 lon: 16.25307 facility: Ospedale Spoke Paola- Cetraro Po Paola - Utic Cardiologia status: RECRUITING city: Paola state: CS zip: 87027 country: Italy name: MARIA T MANES, MD role: CONTACT lat: 39.36313 lon: 16.03691 facility: Policlinico Di Catania Presidio San Marco - Cardiologia Utic status: NOT_YET_RECRUITING city: Catania state: CT zip: 95100 country: Italy name: ALESSIO G LA MANNA, MD role: CONTACT lat: 37.49223 lon: 15.07041 facility: P.O. Garibaldi-Nesima - Arnas Garibaldi - U.O.C. Di Cardiologia Con Utic status: RECRUITING city: Catania state: CT zip: 95122 country: Italy name: MICHELE M GULIZIA, MD role: CONTACT lat: 37.49223 lon: 15.07041 facility: P.O. "Materdomini" - A.O.U. "Renato Dulbecco" - Ssd Cardiologia Riabilitativa status: RECRUITING city: Catanzaro state: CZ zip: 88100 country: Italy name: DOMENICO ZUCCO, MD role: CONTACT lat: 38.88247 lon: 16.60086 facility: Ospedale G.B. Morgagni - L. Pierantoni - U.O. Cardiologia status: RECRUITING city: Forli' state: FC zip: 47121 country: Italy name: DANIELA SPARTA', MD role: CONTACT lat: 44.22177 lon: 12.04144 facility: Arcispedale Sant'Anna - U.O. Cardiologia status: RECRUITING city: Ferrara state: FE zip: 44124 country: Italy name: GABRIELE GUARDIGLI, MD role: CONTACT lat: 44.83804 lon: 11.62057 facility: Policlinico Riuniti - S.C. Di Cardiologia Universitaria-Utic status: RECRUITING city: Foggia state: FG zip: 71100 country: Italy name: NATALE D BRUNETTI, MD role: CONTACT lat: 41.45845 lon: 15.55188 facility: San Francesco Hospital - U.O.C. Cardiologia status: RECRUITING city: Foggia state: FG zip: 71122 country: Italy name: ALDO RUSSO, MD role: CONTACT lat: 41.45845 lon: 15.55188 facility: Ospedale Casa Sollievo Della Sofferenza - Cardiologia - Utic - Riabil Cardiologica status: RECRUITING city: San Giovanni Rotondo state: FG zip: 71013 country: Italy name: GIUSEPPE DI STOLFO, MD role: CONTACT lat: 41.70643 lon: 15.7277 facility: Aou Careggi - Riabilitazione Cardiologica status: RECRUITING city: Firenze state: FI zip: 50134 country: Italy name: COSTANZA BURGISSER, MD role: CONTACT lat: 43.77925 lon: 11.24626 facility: E.O. Ospedali Galliera - S. C. Cardiologia E U.T.I.C. status: RECRUITING city: Genova state: GE zip: 16128 country: Italy name: MARIA MOLFESE, MD role: CONTACT lat: 44.40478 lon: 8.94438 facility: Ospedale San Giovanni Di Dio - Sc Cardiologia (Gorizia-Monfalcone) status: RECRUITING city: Gorizia state: GO zip: 34170 country: Italy name: GERARDINA LARDIERI, MD role: CONTACT lat: 45.94088 lon: 13.62167 facility: Ospedale Civile San Polo - Sc Cardiologia (Gorizia-Monfalcone) status: NOT_YET_RECRUITING city: Monfalcone state: GO zip: 34074 country: Italy name: GERARDINA LARDIERI, MD role: CONTACT lat: 45.80463 lon: 13.53292 facility: Presidio Ospedaliero - U.O. Cardiologia status: RECRUITING city: Sanremo state: IM zip: 18038 country: Italy name: FABIO FERRARI, MD role: CONTACT lat: 43.81725 lon: 7.7772 facility: Ospedale Alessandro Manzoni - S.C. Di Cardiologia status: RECRUITING city: Lecco state: LC zip: 23900 country: Italy name: ROBERTO SPOLADORE, MD role: CONTACT lat: 45.85589 lon: 9.39704 facility: Presidio Ospedaliero F. Ferrari - Ssd Cardiologia - Utic status: RECRUITING city: Casarano state: LE zip: 73042 country: Italy name: DONATO MELISSANO, MD role: CONTACT lat: 40.01131 lon: 18.16237 facility: Ospedale San Giuseppe Da Copertino - U.O. Di Cardiologia status: NOT_YET_RECRUITING city: Copertino state: LE zip: 73043 country: Italy name: ALESSANDRO CALCAGNILE, MD role: CONTACT lat: 40.26821 lon: 18.0543 facility: Ospedale Vito Fazzi - Uoc Cardiologia-Utic Ed Emodinamica status: RECRUITING city: Lecce state: LE zip: 73100 country: Italy name: STEFANIA MARAZIA, MD role: CONTACT lat: 40.35481 lon: 18.17244 facility: Ospedale Ignazio Veris Delli Ponti - Uoc Cardiologia-Utic "E. Vilei" status: RECRUITING city: Scorrano state: LE zip: 73020 country: Italy name: COSIMO A GRECO, MD role: CONTACT lat: 40.09018 lon: 18.29993 facility: Ospedali Riuniti - U.O.C. Cardiologia E Utic status: RECRUITING city: Livorno state: LI zip: 57124 country: Italy name: FRANCESCO BELLINI, MD role: CONTACT lat: 43.54427 lon: 10.32615 facility: Istituto 'Marco Pasquali' Icot - Riabilitazione Cardiologica status: RECRUITING city: Latina state: LT zip: 04100 country: Italy name: ANTONIO GROSSI, MD role: CONTACT lat: 41.46614 lon: 12.9043 facility: Nuovo Ospedale Versilia - Sc Cardiologia status: RECRUITING city: Camaiore state: LU zip: 55041 country: Italy name: GIANCARLO CASOLO, MD role: CONTACT lat: 43.94265 lon: 10.29754 facility: Ospedale Giovanni Paolo Ii - Uosd Utic status: NOT_YET_RECRUITING city: Policoro state: Matera zip: 75025 country: Italy name: ANDREA ANDRIANI, MD role: CONTACT lat: 40.2128 lon: 16.67795 facility: Ospedale Pio Xi - U.O.C. Di Cardiologia status: RECRUITING city: Desio state: MB zip: 20832 country: Italy name: FELICE ACHILLI, MD role: CONTACT lat: 45.61831 lon: 9.20249 facility: Fondazione Irccs San Gerardo Dei Tintori - Ospedale San Gerardo - U.O.C. Cardiologia status: RECRUITING city: Monza state: MB zip: 20900 country: Italy name: LAURA F VALAGUSSA, MD role: CONTACT lat: 45.58005 lon: 9.27246 facility: Ospedale Di Seregno - Riabilitazione Specialistica Cardiologica status: RECRUITING city: Seregno state: MB zip: 20831 country: Italy name: ELISABETTA SCANZIANI, MD role: CONTACT lat: 45.65002 lon: 9.20548 facility: Nuovo Ospedale Di Vimercate - S.C. Cardiologia E Utic status: RECRUITING city: Vimercate state: MB zip: 20871 country: Italy name: DANIELA GRASSELLI, MD role: CONTACT lat: 45.61545 lon: 9.36801 facility: Ospedale Generale Provinciale - U.O. Cardiologia status: RECRUITING city: Macerata state: MC zip: 62100 country: Italy name: MICAELA CAPPONI, MD role: CONTACT lat: 43.29789 lon: 13.45293 facility: Iomi Istituto Ortopedico F. Scalabrino - Uo Cardiologia status: RECRUITING city: Messina state: ME zip: 98015 country: Italy name: ROBERTO CARUSO, MD role: CONTACT lat: 38.19394 lon: 15.55256 facility: Irccs Centro Neurolesi Bonino Pulejo - P.O Piemonte - Cardiologia E Utic status: RECRUITING city: Messina state: ME zip: 98124 country: Italy name: ANTONIO DUCA, MD role: CONTACT lat: 38.19394 lon: 15.55256 facility: Azienda Ospedaliera Papardo - U.O. Cardiologia Con Utic - Emodinamica status: RECRUITING city: Messina state: ME zip: 98158 country: Italy name: VITO PIPITONE, MD role: CONTACT lat: 38.19394 lon: 15.55256 facility: Ospedale Di Cernusco Sul Naviglio - U. O. Di Cardiologia E Ucc status: NOT_YET_RECRUITING city: Cernusco Sul Naviglio state: MI zip: 20063 country: Italy name: SERGIO SALA, MD role: CONTACT lat: 45.52526 lon: 9.33297 facility: Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico - Uoc Malattie Cardiovascolari status: RECRUITING city: Milano state: MI zip: 20122 country: Italy name: STEFANO CARUGO, MD role: CONTACT lat: 45.46427 lon: 9.18951 facility: Centro Cardiologico Monzino Irccs - Terapia Intensiva Cardiologica (Utic) status: RECRUITING city: Milano state: MI zip: 20138 country: Italy name: FILIPPO TOMBARA, MD role: CONTACT lat: 45.46427 lon: 9.18951 facility: Istituti Clinici Scientifici Maugeri Irccs Sede Di Milano - Riabilitazione Cardiologica status: RECRUITING city: Milano state: MI zip: 20138 country: Italy name: MAURIZIO BUSSOTTI, MD role: CONTACT lat: 45.46427 lon: 9.18951 facility: Istituti Clinici Scientifici Maugeri Irccs Sede Di Milano - Uo Cure Subacute status: RECRUITING city: Milano state: MI zip: 20138 country: Italy name: MARCO FROLDI, MD role: CONTACT lat: 45.46427 lon: 9.18951 facility: Irccs Santa Maria Nascente Fond. Don Gnocchi - Cardiologia Riabilitativa status: RECRUITING city: Milano state: MI zip: 20148 country: Italy name: ANDREA A MORASCHI, MD role: CONTACT lat: 45.46427 lon: 9.18951 facility: ASST SANTI PAOLO E CARLO - PO San Carlo - CARDIOLOGIA-UCC status: RECRUITING city: Milano state: MI zip: 20153 country: Italy name: MARTA RESCALDANI, MD role: CONTACT lat: 45.46427 lon: 9.18951 facility: Irccs Ospedale Galeazzi - Sant'Ambrogio - Cardiologia Universitaria Ed Imaging Cardiaco status: RECRUITING city: Milano state: MI zip: 20157 country: Italy name: EDOARDO CONTE, MD role: CONTACT lat: 45.46427 lon: 9.18951 facility: Asst Ospedale Metropolitano Niguarda - Diagnosi E Cure Terr. Malattie Cardiache status: RECRUITING city: Milano state: MI zip: 20159 country: Italy name: GIULIANA G MOMBELLI, MD role: CONTACT lat: 45.46427 lon: 9.18951 facility: Asst Ospedale Metropolitano Niguarda - Cardiologia 1 - Emodinamica status: RECRUITING city: Milano state: MI zip: 20162 country: Italy name: LAURA GARATTI, MD role: CONTACT lat: 45.46427 lon: 9.18951 facility: Asst Ospedale Metropolitano Niguarda - Cardiologia 4 - Diagnostica E Riabilitativa status: RECRUITING city: Milano state: MI zip: 20162 country: Italy name: ALESSANDRO MALOBERTI, MD role: CONTACT lat: 45.46427 lon: 9.18951 facility: Presidio Ospedaliero Di Passirana - Cardiologia Riabilitativa status: RECRUITING city: RHO state: MI zip: 20017 country: Italy name: ANNA FRISINGHELLI, MD role: CONTACT lat: 45.53245 lon: 9.0402 facility: Irccs Policlinico San Donato - Cardiologia Riabilitativa status: RECRUITING city: San Donato Milanese state: MI zip: 20097 country: Italy name: MASSIMO PIEPOLI, MD role: CONTACT lat: 45.41047 lon: 9.26838 facility: Irccs Policlinico Multimedica - Uo Di Cardiologia status: RECRUITING city: Sesto San Giovanni state: MI zip: 20099 country: Italy name: LUCA P ALBERTI, MD role: CONTACT lat: 45.53329 lon: 9.22585 facility: Ospedale Citta' Di Sesto San Giovanni - Sc Cardiologia-Ucc Asst Nord Milano (Bassini-Ssg) status: RECRUITING city: Sesto San Giovanni state: MI zip: 20099 country: Italy name: CAMILLA FACCHINI, MD role: CONTACT lat: 45.53329 lon: 9.22585 facility: Ospedale Santa Maria Bianca - U.O. Di Cardiologia status: RECRUITING city: Mirandola state: MO zip: 41037 country: Italy name: GIULIA NANNI, MD role: CONTACT lat: 44.88515 lon: 11.06902 facility: Ospedale Civile Di Baggiovara - U.O. Di Cardiologia status: RECRUITING city: Modena state: MO zip: 41126 country: Italy name: STEFANIA SANSONI, MD role: CONTACT lat: 44.64783 lon: 10.92539 facility: Ospedale Di Sassuolo - Cardiologia status: RECRUITING city: Sassuolo state: MO zip: 41049 country: Italy name: WALTER SACCO, MD role: CONTACT lat: 44.5432 lon: 10.7848 facility: Ospedale San Giovanni Di Dio - Uo Cardiologia - Utic status: RECRUITING city: Frattamaggiore state: Napoli zip: 80027 country: Italy name: FRANCESCO PIEMONTE, MD role: CONTACT lat: 40.9414 lon: 14.27588 facility: Fondazione G. Giglio - U.O. Di Cardiologia status: RECRUITING city: Cefalu' state: PA zip: 90015 country: Italy name: DONATELLA ARMATA, MD role: CONTACT lat: 38.03856 lon: 14.02285 facility: Ospedale Buccheri La Ferla Fatebenefratelli - Ssd Riabilitazione Cardiovascolare status: RECRUITING city: Palermo state: PA zip: 90123 country: Italy name: FILIPPO M SARULLO, MD role: CONTACT lat: 38.13205 lon: 13.33561 facility: Aou Policlinico P. Giaccone - U.O.C. Cardiologia status: RECRUITING city: Palermo state: PA zip: 90127 country: Italy name: GIUSEPPINA NOVO, MD role: CONTACT lat: 38.13205 lon: 13.33561 facility: Arnas P.O. Civico E Benfratelli - Uoc Utic status: RECRUITING city: Palermo state: PA zip: 90127 country: Italy name: IGNAZIO M SMECCA, MD role: CONTACT lat: 38.13205 lon: 13.33561 facility: Maria Eleonora Hospital - Cardiologia status: RECRUITING city: Palermo state: PA zip: 90135 country: Italy name: VINCENZO PERNICE, MD role: CONTACT lat: 38.13205 lon: 13.33561 facility: Aor Villa Sofia-Cervello P.O. Cervello - U.O. Cardiologia - Cervello status: RECRUITING city: Palermo state: PA zip: 90146 country: Italy name: VINCENZO POLIZZI, MD role: CONTACT lat: 38.13205 lon: 13.33561 facility: Aor Villa Sofia-Cervello Po Villa Sofia - Uoc Cardiologia E Utic E Emodinamica -Villa Sofia status: RECRUITING city: Palermo state: PA zip: 90146 country: Italy name: CARLO CICERONE, MD role: CONTACT lat: 38.13205 lon: 13.33561 facility: Ospedale Unico Della Val Tidone - Cardiologia E Riabilitazione status: RECRUITING city: Castel San Giovanni state: PC zip: 29015 country: Italy name: MARIATERESA DI DIO, MD role: CONTACT lat: 45.06014 lon: 9.43784 facility: Ospedale Civile 'Guglielmo Da Saliceto' - Uoc Cardiologia E Utic status: RECRUITING city: Piacenza state: PC zip: 29100 country: Italy name: DANIELA ASCHIERI, MD role: CONTACT lat: 45.05242 lon: 9.69342 facility: Ospedale Di Cittadella - U.O. Cardiologia status: RECRUITING city: Cittadella state: PD zip: 35013 country: Italy name: GAETANO POVOLO, MD role: CONTACT lat: 45.64523 lon: 11.78453 facility: Ospedale Civile Dello Spirito Santo - Cardiologia Con Utic status: RECRUITING city: Pescara state: PE zip: 65124 country: Italy name: DOMENICO DI CLEMENTE, MD role: CONTACT lat: 42.4584 lon: 14.20283 facility: Presidio Ospedaliero Citta' Di Castello - U.O. Cardiologia/Utic status: RECRUITING city: Citta' Di Castello state: PG zip: 06012 country: Italy name: ANDREA CHIOCCHINI, MD role: CONTACT lat: 43.46556 lon: 12.2375 facility: Ospedale Gubbio-Gualdo Tadino - U.O. Di Utic E Cardiologia status: RECRUITING city: Gubbio state: PG zip: 06024 country: Italy name: DEBORAH COSMI, MD role: CONTACT lat: 43.34996 lon: 12.57309 facility: Azienda Ospedaliera Di Perugia - S.C. Cardiologia status: RECRUITING city: Perugia state: PG zip: 06129 country: Italy name: FRANCESCO NOTARISTEFANO, MD role: CONTACT lat: 43.1122 lon: 12.38878 facility: Ospedale Ss. Cosma E Damiano - Sos Cardiologia status: RECRUITING city: Pescia state: Pistoia zip: 51017 country: Italy name: GAIA C MAGNAGHI, MD role: CONTACT lat: 43.8871 lon: 10.68849 facility: Ospedale Ss. Cosma E Damiano - Sos Riabilitazione Cardiologica status: RECRUITING city: Pescia state: Pistoia zip: 51017 country: Italy name: DUCCIO ROSSINI, MD role: CONTACT lat: 43.8871 lon: 10.68849 facility: Ftgm - Stabilimento Di Pisa - Cardiologia E Medicina Cardiovascolare status: RECRUITING city: Pisa state: PI zip: 56124 country: Italy name: MICHELE EMDIN, MD role: CONTACT lat: 43.70853 lon: 10.4036 facility: Auxilium Vitae Volterra - Riabilitazione Cardiologica status: RECRUITING city: Volterra state: PI zip: 56048 country: Italy name: NICOLA SCELZA, MD role: CONTACT lat: 43.40251 lon: 10.86152 facility: Presidio Ospedaliero Per La Salute Di Sacile - Cardiologia Preventiva E Riabilitativa status: RECRUITING city: Sacile state: PN zip: 33077 country: Italy name: ELISA LEIBALLI, MD role: CONTACT lat: 45.95412 lon: 12.50274 facility: Ospedale Di S. Vito Al Tagliamento - Ssd Cardiologia San Vito - Spilimbergo status: RECRUITING city: San Vito Al Tagliamento state: PN zip: 33078 country: Italy name: DANIELA PAVAN, MD role: CONTACT lat: 45.9168 lon: 12.85945 facility: Ospedale Civile - U.O.C. Cardiologia - Utic status: RECRUITING city: Fidenza state: PR zip: 43036 country: Italy name: GIOVANNI TORTORELLA, MD role: CONTACT lat: 44.86694 lon: 10.06039 facility: Istituto Don Gnocchi - U.O. Prevenzione E Riabilitazione Cardiovascolare status: RECRUITING city: Parma state: PR zip: 43100 country: Italy name: UMBERTO CAMAIORA, MD role: CONTACT lat: 44.79935 lon: 10.32618 facility: Presidio Ospedaliero San Salvatore - Cardiologia E Utic status: RECRUITING city: Pesaro state: PU zip: 61121 country: Italy name: SIMONE MAFFEI, MD role: CONTACT lat: 43.90921 lon: 12.9164 facility: Istituti Clinici Scientifici Maugeri Irccs Sede Di Pavia - U.O. Di Riabilitazione Cardiologica status: RECRUITING city: Pavia state: PV zip: 27100 country: Italy name: GIOVANNI FORNI, MD role: CONTACT lat: 45.19205 lon: 9.15917 facility: Ospedale Civile - U.O. Di Cardiologia status: RECRUITING city: Voghera state: PV zip: 27058 country: Italy name: TIZIANA SPEZZANO, MD role: CONTACT lat: 44.99151 lon: 9.01175 facility: Ospedale Civile - Uo Servizio Cardiologia status: RECRUITING city: Lugo state: RA zip: 48022 country: Italy name: GIULIA RICCI LUCCHI, MD role: CONTACT lat: 44.42137 lon: 11.91094 facility: Ospedale Civile Santa Maria Delle Croci - Uoc Cardiologia status: RECRUITING city: Ravenna state: RA zip: 48121 country: Italy name: ANDREA RUBBOLI, MD role: CONTACT lat: 44.41344 lon: 12.20121 facility: Ospedale Civile Di Guastalla - Sos Cardiologia E Riabilitazione Card Area Nord status: RECRUITING city: Guastalla state: RE zip: 42016 country: Italy name: ALESSANDRO NAVAZIO, MD role: CONTACT lat: 44.91172 lon: 10.66186 facility: Ospedale E. Franchini - S.O.S. Cardiologia status: RECRUITING city: Montecchio Emilia state: RE zip: 42027 country: Italy name: ELISABETTA CATELLANI, MD role: CONTACT lat: 44.69937 lon: 10.45211 facility: Po Santa Maria Nuova - Ausl Re Irccs - Soc Cardiologia Ospedaliera status: RECRUITING city: Reggio Emilia state: RE zip: 42100 country: Italy name: ALESSANDRO NAVAZIO, MD role: CONTACT lat: 44.69825 lon: 10.63125 facility: Ospedale Riccardo Guzzardi - U.O.C. Di Cardiologia-Utic status: RECRUITING city: Vittoria state: RG zip: 97019 country: Italy name: GIUSEPPE DI STABILE, MD role: CONTACT lat: 36.95151 lon: 14.52788 facility: P.O. San Camillo de Lellis - U.O.C. Cardiologia status: RECRUITING city: Rieti state: RI zip: 02100 country: Italy name: AMIR KOL, MD role: CONTACT lat: 42.40476 lon: 12.85735 facility: Ospedali Riuniti Anzio-Nettuno - U.O.C. Di Cardiologia - Utic status: RECRUITING city: Anzio state: RM zip: 00042 country: Italy name: NATALE DI BELARDINO, MD role: CONTACT lat: 41.45263 lon: 12.62157 facility: Ospedale Dei Castelli - U.O.C. Di Cardiologia E Utic status: RECRUITING city: Ariccia state: RM zip: 00072 country: Italy name: FRANCESCO MONTI, MD role: CONTACT lat: 41.72063 lon: 12.6723 facility: Ospedale Civile San Paolo - U.O.C. Cardiologia - Utic status: RECRUITING city: Civitavecchia state: RM zip: 00053 country: Italy name: SIMONE CALCAGNO, MD role: CONTACT lat: 42.09325 lon: 11.79674 facility: Ospedale L. Parodi Delfino - U.O.C. Di Cardiologia - Utic status: NOT_YET_RECRUITING city: Colleferro state: RM zip: 00034 country: Italy name: ROBERTA IPPEDICO, MD role: CONTACT lat: 41.72722 lon: 13.00481 facility: Icr Villa Delle Querce - Riabilitazione Cardiorespiratoria status: NOT_YET_RECRUITING city: Nemi state: RM zip: 00040 country: Italy name: MICHELE AZZARITO, MD role: CONTACT lat: 41.72185 lon: 12.71809 facility: P.O. San Filippo Neri - Asl Roma 1 - Cardiologia Clinica E Riabilitativa status: RECRUITING city: Roma state: RM zip: 00135 country: Italy name: FURIO COLIVICCHI, MD role: CONTACT lat: 41.89193 lon: 12.51133 facility: Inmi Lazzaro Spallanzani Irccs - Servizio Di Cardiologia Del Dipartimento Clinico status: RECRUITING city: Roma state: RM zip: 00149 country: Italy name: MARIA C GATTO, MD role: CONTACT lat: 41.89193 lon: 12.51133 facility: Ospedale San Camillo - Uoc Cardiologia status: RECRUITING city: Roma state: RM zip: 00152 country: Italy name: LEONARDO DE LUCA, MD role: CONTACT lat: 41.89193 lon: 12.51133 facility: Ospedale Sandro Pertini - Uoc Cardiologia status: RECRUITING city: Roma state: RM zip: 00157 country: Italy name: ANTONINO GRANATELLI, MD role: CONTACT lat: 41.89193 lon: 12.51133 facility: Ospedale Sandro Pertini - Uosd Cardiologia D'Urgenza status: RECRUITING city: Roma state: RM zip: 00157 country: Italy name: STEFANIA CHERUBINI, MD role: CONTACT lat: 41.89193 lon: 12.51133 facility: Fondazione Policlinico Universitario A. Gemelli Irccs - Uosd Cardiologia D'Urgenza status: NOT_YET_RECRUITING city: Roma state: RM zip: 00168 country: Italy name: GIOVANNA LIUZZO, MD role: CONTACT lat: 41.89193 lon: 12.51133 facility: Policlinico Casilino - U.O.C. Cardiologia status: RECRUITING city: Roma state: RM zip: 00169 country: Italy name: LEONARDO CALO', MD role: CONTACT lat: 41.89193 lon: 12.51133 facility: Osp. Fatebenefratelli Isola Tiberina - Uoc Cardiologia Diagnostica Interventistica-Utic status: NOT_YET_RECRUITING city: Roma state: RM zip: 00188 country: Italy name: MATTEO RUZZOLINI, MD role: CONTACT lat: 41.89193 lon: 12.51133 facility: Ospedale Sant'Andrea Di Roma - U.O.C. Cardiologia status: RECRUITING city: Roma state: RM zip: 00189 country: Italy name: EMANUELE BARBATO, MD role: CONTACT lat: 41.89193 lon: 12.51133 facility: Ospedale Santo Spirito - Uoc Cardiologia status: RECRUITING city: Roma state: RM zip: 00193 country: Italy name: MARINA DELFINI, MD role: CONTACT lat: 41.89193 lon: 12.51133 facility: Ospedale San Giovanni Evangelista - U.O.C. Di Cardiologia - Utic status: RECRUITING city: Tivoli state: RM zip: 00019 country: Italy name: ALFREDO POSTERARO, MD role: CONTACT lat: 41.95952 lon: 12.8016 facility: Ospedale Infermi - U.O. Cardiologia status: NOT_YET_RECRUITING city: Rimini state: RN zip: 47900 country: Italy name: ANDREA GARDI, MD role: CONTACT lat: 44.05755 lon: 12.56528 facility: Ospedale Maria Ss. Addolorata - U.O. Di Cardiologia Utic status: RECRUITING city: Eboli state: SA zip: 84025 country: Italy name: EDUARDO CAPUANO, MD role: CONTACT lat: 40.61747 lon: 15.05693 facility: Presidio Ospedaliero Umberto I - Uoc Cardiologia - Utic status: RECRUITING city: Nocera Inferiore state: SA zip: 84014 country: Italy name: MARIO PACILEO, MD role: CONTACT lat: 40.7454 lon: 14.64542 facility: Presidio Ospedaliero Luigi Curto - Uo Cardiologia-Utic status: RECRUITING city: Polla state: SA zip: 84035 country: Italy name: SILVIO SAPONARA, MD role: CONTACT lat: 40.51433 lon: 15.49715 facility: Aou S. Giovanni Di Dio-Ruggi D'Aragona - Cardiologia Intensiva Ospedaliera status: RECRUITING city: Salerno state: SA zip: 84131 country: Italy name: MICHELE R DI MURO, MD role: CONTACT lat: 40.67545 lon: 14.79328 facility: Aou S. Giovanni Di Dio-Ruggi D'Aragona - Ssd Utic status: RECRUITING city: Salerno state: SA zip: 84131 country: Italy name: AMELIA RAVERA, MD role: CONTACT lat: 40.67545 lon: 14.79328 facility: Aou S. Giovanni Di Dio-Ruggi D'Aragona - Uoc Clinica Cardiologica status: RECRUITING city: Salerno state: SA zip: 84131 country: Italy name: MICHELE CICCARELLI, MD role: CONTACT lat: 40.67545 lon: 14.79328 facility: Ospedale Villa Malta - Cardiologia E Utic status: RECRUITING city: Sarno state: SA zip: 84087 country: Italy name: MARIA C RUSSO, MD role: CONTACT lat: 40.80748 lon: 14.62151 facility: Ospedale San Luca - U.O. Utic - Cardiologia status: RECRUITING city: Vallo Della Lucania state: SA zip: 84078 country: Italy name: ANTONIO ALOIA, MD role: CONTACT lat: 40.22786 lon: 15.26635 facility: Aou Senese Ospedale S. Maria Alle Scotte - Cardiologia status: RECRUITING city: Siena state: SI zip: 53100 country: Italy name: SERAFINA VALENTE, MD role: CONTACT lat: 43.31822 lon: 11.33064 facility: Ospedale San Bartolomeo - Sc Riabilitazione Cardiologica status: RECRUITING city: Sarzana state: SP zip: 19038 country: Italy name: DANIELE BERTOLI, MD role: CONTACT lat: 44.11178 lon: 9.9622 facility: P.O. Lentini - Uosd Di Cardiologia Con Utic status: RECRUITING city: Lentini state: SR zip: 96016 country: Italy name: VINCENZO CRISCI, MD role: CONTACT lat: 37.28556 lon: 14.99737 facility: Ospedale Ss. Annunziata - Cardiologia Clinica Ed Interventistica status: RECRUITING city: Sassari state: SS zip: 07100 country: Italy name: GAVINO CASU, MD role: CONTACT lat: 40.72586 lon: 8.55552 facility: Po Ponente - Ospedale Santa Corona - Sc Cardiologia Ponente status: RECRUITING city: Pietra Ligure state: SV zip: 17027 country: Italy name: CHIARA BERNELLI, MD role: CONTACT lat: 44.1492 lon: 8.28206 facility: Casa Di Cura Villa Verde - Cardiologia status: RECRUITING city: Taranto state: TA zip: 74100 country: Italy name: ANNA N JOHN, MD role: CONTACT lat: 40.46435 lon: 17.24707 facility: Osp. San Pancrazio-Santo Stefano - Riabilitazione Cardiologica status: RECRUITING city: Arco state: TN zip: 38062 country: Italy name: GIOVANNI CIOFFI, MD role: CONTACT lat: 45.91772 lon: 10.88672 facility: Ospedale Santa Chiara - Divisione Di Cardiologia status: RECRUITING city: Trento state: TN zip: 38122 country: Italy name: FILIPPO ZILIO, MD role: CONTACT lat: 46.06787 lon: 11.12108 facility: Por Cirie' Lanzo Presidio Cirie' - S.C. Cardiologia status: RECRUITING city: Ciriè state: TO zip: 10073 country: Italy name: Michele Capriolo, MD role: CONTACT lat: 45.23486 lon: 7.60125 facility: Aou San Luigi Gonzaga - S.C.D.O. Cardiologia status: RECRUITING city: Orbassano state: TO zip: 10043 country: Italy name: Carloalberto Biolù, MD role: CONTACT lat: 45.00547 lon: 7.53813 facility: Casa Di Cura Villa Serena - Riabilitazione Cardiorespiratoria status: RECRUITING city: Piossasco state: TO zip: 10045 country: Italy name: ALEX MICANTI, MD role: CONTACT lat: 44.98802 lon: 7.4601 facility: Ospedale Degli Infermi - Sc Cardiologia status: RECRUITING city: Rivoli state: TO zip: 10098 country: Italy name: EMANUELE TIZZANI, MD role: CONTACT lat: 45.07073 lon: 7.51465 facility: Ospedale San Giovanni Bosco - Sc Cardiologia status: RECRUITING city: Torino state: TO zip: 10154 country: Italy name: MAURIZIO BERTAINA, MD role: CONTACT lat: 45.07049 lon: 7.68682 facility: Casa Di Cura Pineta Del Carso - U.O. Riabilitazione Cardiologica status: RECRUITING city: Aurisina state: TS zip: 34011 country: Italy name: LARA GOMBAC, MD role: CONTACT lat: 45.74968 lon: 13.67345 facility: Asugi Trieste - Sc Patologie Cardiovascolari status: RECRUITING city: Trieste state: TS zip: 34125 country: Italy name: LUISA MATTEI, MD role: CONTACT lat: 45.64953 lon: 13.77679 facility: Pou "Santa Maria Della Misericordia" - S.O.C. Cardiologia status: RECRUITING city: Udine state: UD zip: 33100 country: Italy name: MARIZA DE BIASIO, MD role: CONTACT lat: 46.0693 lon: 13.23715 facility: Ospedale Multimedica Castellanza - Cardiologia status: RECRUITING city: Castellanza state: VA zip: 21053 country: Italy name: ANNA PICOZZI, MD role: CONTACT lat: 45.61079 lon: 8.89616 facility: Presidio Ospedaliero Di Saronno - U.O.C. Di Cardiologia status: RECRUITING city: Saronno state: VA zip: 21047 country: Italy name: DANIELE NASSIACOS, MD role: CONTACT lat: 45.62513 lon: 9.03517 facility: Ospedale Di Circolo Galmarini - Cardiologia status: NOT_YET_RECRUITING city: Tradate state: VA zip: 21049 country: Italy name: MASSIMO BIGNOTTI, MD role: CONTACT lat: 45.70843 lon: 8.90763 facility: Ospedale Sant'Andrea - Sc Cardiologia status: RECRUITING city: Vercelli state: VC zip: 13100 country: Italy name: MARIA BERTOLAZZI, MD role: CONTACT lat: 45.32163 lon: 8.41989 facility: Ospedale Dell'Angelo - U.O.C. Cardiologia status: RECRUITING city: Mestre state: VE zip: 30171 country: Italy name: SAKIS THEMISTOCLAKIS, MD role: CONTACT lat: 45.49167 lon: 12.24538 facility: Policlinico San Marco - Riabilitazione Cardiologica status: RECRUITING city: Mestre state: VE zip: 30173 country: Italy name: FRANCO DEL PICCOLO, MD role: CONTACT lat: 45.49167 lon: 12.24538 facility: Ospedale P.F. Calvi - Uos Di Cardiologia Riabilitativa status: RECRUITING city: Noale state: VE zip: 30033 country: Italy name: VALENTINA PESCATORE, MD role: CONTACT lat: 45.54596 lon: 12.06445 facility: Ospedale Civile - U.O.C. Di Cardiologia status: NOT_YET_RECRUITING city: San Dona' Di Piave state: VE zip: 30027 country: Italy name: LEONARDO DI ASCENZO, MD role: CONTACT lat: 45.63019 lon: 12.5681 facility: Ospedale Civile - U.O.C. Di Cardiologia status: RECRUITING city: Arzignano state: VI zip: 36071 country: Italy name: CLAUDIO BILATO, MD role: CONTACT lat: 45.52027 lon: 11.33446 facility: Ospedale Alto Vicentino - U.O.C. Cardiologia - Ucic status: RECRUITING city: Santorso state: VI zip: 36014 country: Italy name: GIOVANNI MORANI, MD role: CONTACT lat: 45.73383 lon: 11.38785 facility: Ospedale Civile San Bortolo - U.O.C. Cardiologia status: RECRUITING city: Vicenza state: VI zip: 36100 country: Italy name: VALENTINA SIVIERO, MD role: CONTACT lat: 45.54672 lon: 11.5475 facility: Irccs Ospedale Sacro Cuore Don Calabria - U.O. Di Cardiologia status: RECRUITING city: Negrar state: VR zip: 37024 country: Italy name: GIULIO MOLON, MD role: CONTACT lat: 45.52918 lon: 10.93899 facility: Ospedale G. Fracastoro - U.O.C. Di Cardiologia status: RECRUITING city: San Bonifacio state: VR zip: 37047 country: Italy name: MAURIZIO ANSELMI, MD role: CONTACT lat: 45.39595 lon: 11.27352 facility: Aoui Di Verona - U.O. Cardiologia status: RECRUITING city: Verona state: VR zip: 37126 country: Italy name: MARIA G GASPARI, MD role: CONTACT lat: 45.4299 lon: 10.98444 facility: Ospedale Belcolle - Uoc Cardiologia Ed Emodinamica status: RECRUITING city: Viterbo state: VT zip: 01100 country: Italy name: LUIGI SOMMARIVA, MD role: CONTACT lat: 42.41937 lon: 12.1056 facility: Ospedale Ss. Trinita' - S.C. Di Cardiologia status: RECRUITING city: Borgomanero zip: 28021 country: Italy name: PIERFRANCO S DELLAVESA, MD role: CONTACT lat: 45.69873 lon: 8.4623 facility: Istituti Clinici Scientifici Maugeri Irccs Sede Di Veruno - Uo Cardiologia Riabilitativa status: RECRUITING city: Gattico zip: 28013 country: Italy name: MASSIMO PISTONO, MD role: CONTACT lat: 45.70717 lon: 8.52003 facility: Presidio Ospedaliero San Giugliano - U.O. Cardiologia - Utic status: RECRUITING city: Giugliano in Campania zip: 80014 country: Italy name: GIOVANNI NAPOLITANO, MD role: CONTACT lat: 40.92849 lon: 14.20197 facility: Ospedale Madonna Delle Grazie - Ssd Utic status: NOT_YET_RECRUITING city: Matera zip: 75100 country: Italy name: MICHELE A CLEMENTE, MD role: CONTACT lat: 40.66599 lon: 16.60463 facility: Ospedale Buon Consiglio Fatebenefratelli - U.O.Complessa Di Cardiologia E Utic status: RECRUITING city: Napoli zip: 80123 country: Italy name: GAETANO M RUOCCO, MD role: CONTACT lat: 40.85216 lon: 14.26811 facility: Aorn Cardarelli - U.O. Cardiologia Con Utic status: RECRUITING city: Napoli zip: 80131 country: Italy name: CIRO MAURO, MD role: CONTACT lat: 40.85216 lon: 14.26811 facility: Aorn Ospedale Dei Colli - P.O. Monaldi - Uosd Malattie Cardiologiche Congenite Adulti-Guch status: RECRUITING city: Napoli zip: 80131 country: Italy name: BERARDO SARUBBI, MD role: CONTACT lat: 40.85216 lon: 14.26811 facility: Ospedale Dei Pellegrini - Uoc Cardiologia-Utic status: NOT_YET_RECRUITING city: Napoli zip: 80134 country: Italy name: GIUSEPPE BRUZZESE, MD role: CONTACT lat: 40.85216 lon: 14.26811 facility: Ospedale S. Giovanni Bosco - Sc Cardiologia - Utic status: RECRUITING city: Napoli zip: 80134 country: Italy name: PAOLO TAMMARO, MD role: CONTACT lat: 40.85216 lon: 14.26811 facility: Ospedale Del Mare - U.O. Cardiologia Con Utic-Emodinamica status: RECRUITING city: Napoli zip: 80147 country: Italy name: BERNARDINO TUCCILLO, MD role: CONTACT lat: 40.85216 lon: 14.26811 facility: Aou Maggiore Della Carita' - Scdo Cardiologia Ii status: RECRUITING city: Novara zip: 28100 country: Italy name: LIDIA ROSSI, MD role: CONTACT lat: 45.44694 lon: 8.62118 facility: Clinica San Gaudenzio - Uoa Cardiologia status: RECRUITING city: Novara zip: 28100 country: Italy name: NADIA PODIMANI, MD role: CONTACT lat: 45.44694 lon: 8.62118 facility: Ospedale Santa Maria Delle Grazie - U.O. Cardiologia - Utic Con Emodinamica status: NOT_YET_RECRUITING city: Pozzuoli zip: 80078 country: Italy name: GIANLUIGI TAGLIAMONTE, MD role: CONTACT lat: 40.84394 lon: 14.0952 facility: Ospedale Mauriziano Umberto I - Sc Cardiologia status: RECRUITING city: Torino zip: 10128 country: Italy name: Giuseppe Musumeci, MD role: CONTACT lat: 45.07049 lon: 7.68682 hasResults: False
|
<|newrecord|> nctId: NCT06275100 id: HUTH briefTitle: PREhabilitation in Patients Awaiting Acute Inpatient Cardiac SurgEry acronym: (PREP-ACE) overallStatus: RECRUITING date: 2024-04-03 date: 2024-12 date: 2025-06 date: 2024-02-23 date: 2024-04-09 name: University of Hull class: OTHER briefSummary: This is a single centre, single arm pilot feasibility study to determine the feasibility and practicality of prehabilitation in acute inpatients waiting for cardiac surgery. We will be looking into participant eligibility, acceptability, recruitment rates, completion rates and barriers to implementing a prehabilitation programme. Secondary outcomes include safety (incidence of adverse events directly related to the study), improvement in 6 minutes walk test (6MWT), hand grip strength, quality of life, and spirometry. At the end of the trial, we will be seeking the feedback of the participants to help us improve the design further. conditions: Cardiac Disease conditions: Aortic Valve Disease conditions: Coronary Artery Disease conditions: Endocarditis conditions: Valve Heart Disease studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Single arm pilot feasibility study in acute inpatients waiting for cardiac surgery. Intervention is a prehabilitation program primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 20 type: ESTIMATED name: Prehabilitation measure: Feasibility of prehabilitation in acute inpatients waiting for cardiac surgery measure: Efficacy of prehabilitation measure: Efficacy of prehabilitation measure: Efficacy of prehabilitation measure: Efficacy of prehabilitation measure: Efficacy of prehabilitation measure: Complication rate measure: Safety of Prehabilitation in acute inpatients waiting for surgery sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hull University Teaching Hospital status: RECRUITING city: Hull zip: HU1 3DR country: United Kingdom lat: 53.7446 lon: -0.33525 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2023-11-06 uploadDate: 2024-02-15T17:59 filename: Prot_000.pdf size: 146015 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-11-06 uploadDate: 2024-02-15T18:01 filename: ICF_001.pdf size: 107547 hasResults: False
|
<|newrecord|> nctId: NCT06275087 id: situm1phd briefTitle: Differences in Speed of Recovery From Anesthesia for Intraoral Surgery acronym: PSIOS overallStatus: RECRUITING date: 2024-04-10 date: 2026-03 date: 2026-07 date: 2024-02-23 date: 2024-04-22 name: Clinical Hospital Centre Zagreb class: OTHER briefSummary: The goal of this clinical trial is to compare two groups of patients going in general anesthesia for intraoral surgery, the first group TIVA with propofol and the second group inhalational with sevoflurane. The main questions it aims to answer are to asses speed and quality of recovery from general anesthesia.
|
Participants will fill out a questionnaire to evaluate the quality of recovery from anesthesia using the QoR-40 1h, 24h, and 30 days after waking up from anesthesia in comparison to the results of the same questionnaire before surgery. Also, the investigators will perform a hand grip and bite strength test on the patients after waking up from anesthesia in the operating room, after 1 hour in the recovery room, and after 24 hours compared to preoperative values.
|
The investigators will compare TIVA and Volatile groups to see if there are any differences in recovery seed, muscle strength recovery, postoperative nausea and vomiting, and shivering between groups. conditions: Intraoral Tumor studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 42 type: ESTIMATED name: Propofol name: Sevoflurane measure: "Quality of recovery from anesthesia" QoR-40 questionnaire measure: bite strength and hand grip strength measure: Postoperative nausea and vomiting measure: Postoperative shivering sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Centre Zagreb status: RECRUITING city: Zagreb zip: 10000 country: Croatia name: Ivan Šitum role: CONTACT phone: 0915143620 email: [email protected] name: Ivan Šitum role: PRINCIPAL_INVESTIGATOR lat: 45.81444 lon: 15.97798 hasResults: False
|
<|newrecord|> nctId: NCT06275074 id: 23-007716 briefTitle: Dry Needling and Therapeutic Exercise on Sleep in Individuals With Chronic Neck Pain and Sleep Disturbance overallStatus: RECRUITING date: 2024-03-14 date: 2024-09-01 date: 2025-03-01 date: 2024-02-23 date: 2024-04-05 name: Mayo Clinic class: OTHER briefSummary: Feasibility study investigating the effects of dry needling on individuals with chronic neck pain and sleep disturbance. conditions: Neck Pain conditions: Sleep Disturbance studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE maskingDescription: Outcome assessors will be blinded to group assignment of participants. whoMasked: OUTCOMES_ASSESSOR count: 28 type: ESTIMATED name: Dry Needling name: Therapeutic Exercise measure: Participant retention rate measure: Participant intervention adherence measure: Number of adverse responses to treatment measure: Sleep Duration measure: Sleep Quality measure: Disability Level measure: Pain Level sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic - Motion Analysis Lab status: RECRUITING city: Rochester state: Minnesota zip: 55905 country: United States name: Ray Lunasin role: CONTACT phone: 507-538-0839 email: [email protected] lat: 44.02163 lon: -92.4699 hasResults: False
|
<|newrecord|> nctId: NCT06275061 id: KY-2020-021 briefTitle: Chinese Obesity and MEtabolic Surgery Database (COMES Database) acronym: COMES overallStatus: RECRUITING date: 2020-05-01 date: 2030-12-31 date: 2040-12-31 date: 2024-02-23 date: 2024-02-23 name: Jinan University Guangzhou class: OTHER name: Chinese Obesity and Metabolic Surgery Collaborative briefSummary: The purpose of the Chinese Obesity and MEtabolic Surgery Database (COMES Database) is to collect data and examine the long-term effects of metabolic and bariatric surgery on obesity and metabolic disorders in the Chinese population. conditions: Obesity conditions: Metabolic Surgery conditions: Bariatric Surgery conditions: Weight Loss studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1000000 type: ESTIMATED name: Metabolic and Bariatric Surgery measure: Excess weight loss effect of metabolic and bariatric surgery after 1 year measure: Excess weight loss effect of metabolic and bariatric surgery in long-term follow-ups measure: Excess weight loss effect of metabolic and bariatric surgery in long-term follow-ups measure: Excess weight loss effect of metabolic and bariatric surgery in long-term follow-ups measure: Glycemic control effect of metabolic and bariatric surgery after 1 year measure: Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups measure: Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups measure: Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups measure: Glycemic control effect of metabolic and bariatric surgery after 1 year measure: Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups measure: Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups measure: Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups measure: Glycemic control effect of metabolic and bariatric surgery after 1 year measure: Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups measure: Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups measure: Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups measure: Glycemic control effect of metabolic and bariatric surgery after 1 year measure: Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups measure: Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups measure: Glycemic control effect of metabolic and bariatric surgery in long-term follow-ups measure: Adverse events rate of metabolic and bariatric surgery sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Jinan University status: RECRUITING city: Guangzhou state: Guangdong zip: 510630 country: China name: Wah Yang, MD role: CONTACT phone: +8615920373823 email: [email protected] lat: 23.11667 lon: 113.25 hasResults: False
|
<|newrecord|> nctId: NCT06275048 id: STUDY00006302 briefTitle: The Influence of Oral Contraceptives During Disuse overallStatus: RECRUITING date: 2024-01-26 date: 2024-12 date: 2025-05 date: 2024-02-23 date: 2024-02-23 name: University of Central Florida class: OTHER briefSummary: Studies across various sports and physical activities have consistently shown that females incur more injuries compared to their male counterparts, but the underlying reasons for this disparity remain poorly understood. While differences in hormone levels between males and females have been speculated to play a role, very little rigorous research has been conducted to directly examine potential connections between sex hormones and injury risk. Specifically, females have been shown to be at greater risk for hand and wrist injuries. The higher injury incidence begins at puberty and persists across the lifespan, suggesting a link to hormonal factors. However, significant gaps remain in understanding the relationships between the menstrual cycle, exogenous hormones from birth control, and risk factors for sports-related injury in females. The purpose of this study is to examine changes in muscle strength and neuromuscular activation among females using monophasic oral contraceptives, females not using oral contraceptives, and males during one week of wrist/hand immobilization. conditions: Oral Contraceptives conditions: Rehabilitation conditions: Menstrual Cycle conditions: Physical Therapy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 60 type: ESTIMATED name: Wrist/hand immobilization measure: Grip Strength measure: Muscle activation sex: ALL minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: University of Central Florida status: RECRUITING city: Orlando state: Florida zip: 32816 country: United States name: Matt S Stock, Ph.D. role: CONTACT phone: 407-823-0364 email: [email protected] name: Matt S Stock, Ph.D. role: PRINCIPAL_INVESTIGATOR lat: 28.53834 lon: -81.37924 hasResults: False
|
<|newrecord|> nctId: NCT06275035 id: 4235 briefTitle: Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI acronym: MEMENTO overallStatus: RECRUITING date: 2024-02-22 date: 2026-01 date: 2031-01 date: 2024-02-23 date: 2024-03-01 name: Tata Memorial Centre class: OTHER briefSummary: The goal of this clinical trial is to evaluate the role of memantine in preservation of memory and neurocognition in patients undergoing craniospinal irradiation. Participants will be randomised into two arms and the interventional arm will receive memantine along with the standard treatment. Researchers will compare the neurocognitive tests of participants in both the arms to see if memantine leads to significant preservation of memory and cognition post radiation therapy. conditions: Neurocognitive Dysfunction studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 101 type: ESTIMATED name: Memantine Oral Tablet measure: Cognitive-deterioration-free survival at 2 years measure: Full-Scale Intelligence Quotient (FSIQ) in children measure: Overall survival (OS) measure: Academic performance by scholastic performance and grades measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of Memantine measure: Progression-Free Survival (PFS) measure: Full-Scale Intelligence Quotient (FSIQ) in adults measure: Full Scale Intelligence Quotient change in subgroups measure: Radiological features of cognitive decline on Magnetic Resonance Imaging measure: Neuroinflammatory markers correlation with neurocognitive decline and survival sex: ALL minimumAge: 5 Years maximumAge: 39 Years stdAges: CHILD stdAges: ADULT facility: Tata Memorial Hospital status: RECRUITING city: Mumbai state: Maharashtra zip: 400012 country: India name: Dr Tejpal Gupta, MD role: CONTACT phone: 022-24177000 phoneExt: 6015 email: [email protected] lat: 19.07283 lon: 72.88261 hasResults: False
|
<|newrecord|> nctId: NCT06275022 id: NanjingCH011665 briefTitle: A Prospective Study on the Treatment of cLM Based on ICG Imaging overallStatus: RECRUITING date: 2023-01-01 date: 2025-12-31 date: 2026-06-30 date: 2024-02-23 date: 2024-02-23 name: Nanjing Children's Hospital class: OTHER briefSummary: The goal of this prospective randomized controlled study is to explore the role of indocyanine green-fluorescence imaging in management of cystic lymphatic malformation.. To clarify the application value of indocyanine green-fluorescence imaging in both diagnosis and treatment of cystic lymphatic malformation (cLM) in children, is helpful for exploring pathogenesis of cLM, and providing a clearer scientific basis for subsequent surgical intervention. It also provides alternative for the future diagnosis and treatment of cLM.
|
Participants will receive indocyanine green-fluorescence imaging before operation, while the patients in control group will receive traditional operation.
|
Researchers will compare difference in curative effect between two groups. conditions: Lymphatic Malformation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 110 type: ESTIMATED name: Inflow occlusion with perforation of septation and sclerotherapy name: Perforation of septation and sclerotherapy name: Indocyanine green-guided partial resection and sclerotherapy name: Partial resection and sclerotherapy measure: Cure rate measure: Effective rate measure: Treatment frequency measure: Likert score measure: Wound infection measure: Delayed healing measure: Pigmentation sex: ALL minimumAge: 30 Days maximumAge: 16 Years stdAges: CHILD facility: Children's hospital of Nanjing medical university status: RECRUITING city: Nanjing state: Jiangsu zip: 210008 country: China name: Tao Han, Dr. role: CONTACT phone: +86 186 5190 3495 email: [email protected] lat: 32.06167 lon: 118.77778 hasResults: False
|
<|newrecord|> nctId: NCT06275009 id: 2023-1990 briefTitle: Chinese Occupational Population Cohort of Lifestyle and Physical Fitness (LiFitChina) acronym: LiFitChina overallStatus: RECRUITING date: 2023-12-11 date: 2026-12-11 date: 2026-12-11 date: 2024-02-23 date: 2024-02-28 name: China National Center for Cardiovascular Diseases class: OTHER_GOV briefSummary: The incidence and prevalence of metabolic risk factors such as obesity, hypertension, diabetes, and dyslipidemia, as well as cardiovascular diseases (CVD), are continuously rising among the occupational population in China, primarily comprising the middle-aged and young adults. Unhealthy lifestyles and declining physical fitness are independent risk factors affecting cardiovascular health. Additionally, the level of physical fitness is influenced by postnatal lifestyles. Lifestyle factors related to cardiovascular health in the occupational population encompass various aspects, including smoking, physical activity, diet, sleep, psychological stress, etc. These factors may interact or have a synergistic effect, necessitating a comprehensive assessment.
|
This project proposes a prospective cohort study design to establish a monitoring cohort for lifestyle and physical fitness among the occupational population. The study will track and follow individuals with or without any CVD metabolic risk factors, collecting information on general status, lifestyle, physical fitness, and health examination data. Exposure factors such as lifestyle and physical fitness will be measured annually, and the occurrence of CVD-related health outcomes will be observed. The aim is to develop a comprehensive evaluation index for cardiovascular health lifestyle, analyze the direct and indirect impacts of lifestyle and physical fitness on the occurrence and development of CVD, and explore potential mediating and moderating effects of physical fitness in the association between lifestyle and cardiovascular health. conditions: Lifestyle conditions: Physical Fitness conditions: Cardiovascular Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 18512 type: ESTIMATED measure: the composite end point of new major adverse cardiovascular events measure: new incidence of each major adverse cardiovascular events measure: new incidence of cancer measure: new incidence of all-cause death measure: level of systolic pressure measure: level of diastolic pressure measure: level of blood lipid measure: level of BMI measure: level of maximal oxygen uptake (VO2max) measure: level of metabolic equivalents (METs) sex: ALL minimumAge: 18 Years maximumAge: 59 Years stdAges: ADULT facility: Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College status: RECRUITING city: Beijing state: Beijing country: China name: Xue Feng, MD PhD role: CONTACT phone: +86-15601378512 email: [email protected] lat: 39.9075 lon: 116.39723 hasResults: False
|
<|newrecord|> nctId: NCT06274996 id: 2024ZSLYEC-063 briefTitle: Efficacy and Safety Analysis of Upadacitinib in Inflammatory Bowel Disease overallStatus: COMPLETED date: 2021-01-01 date: 2023-12-31 date: 2023-12-31 date: 2024-02-23 date: 2024-02-23 name: Sixth Affiliated Hospital, Sun Yat-sen University class: OTHER briefSummary: This study focuses on evaluating Upadacitinib, a new oral medication that inhibits specific enzymes involved in inflammation, for treating inflammatory bowel disease (IBD), which includes conditions such as Crohn\'s Disease and Ulcerative Colitis. The goal is to determine how effective and safe this drug is for patients in China, where data is currently lacking.IBD significantly affects individuals\' quality of life and imposes a high burden on society and healthcare systems. Current treatments don\'t work for everyone, and some patients may need surgery. Upadacitinib has shown promise in other countries for treating IBD and related conditions and has been approved by the US FDA for such use.
|
Our study is retrospective and multicenter, meaning it will look back at patient records from multiple hospitals to analyze the outcomes of those who have received Upadacitinib. Investigators aim to enroll patients treated between January 2020 and December 2023, focusing on adults who have taken Upadacitinib for at least 8 weeks.For patients, families, and healthcare providers, this research could mean a potential new treatment option for IBD. Understanding Upadacitinib\'s efficacy and safety could lead to better management of the disease, possibly reducing the need for surgery and improving the quality of life for those affected by IBD. The ultimate goal is to provide more personalized and effective treatment strategies for IBD patients in China. conditions: Inflammatory Bowel Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 81 type: ACTUAL name: Upadacitinib measure: Steroid-Free Clinical Remission measure: Clinical Response measure: Endoscopic Remission measure: Mucosal Healing measure: Radiological remission measure: Radiological response sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: the Sixth Affiliated Hospital of Sun Yat-Sen University city: Guangzhou state: Guangdong zip: 510655 country: China lat: 23.11667 lon: 113.25 hasResults: False
|
<|newrecord|> nctId: NCT06274983 id: SCH-2629 briefTitle: DMD- Interactive Virtual Reality Study acronym: DMD-IVR overallStatus: ACTIVE_NOT_RECRUITING date: 2023-04-20 date: 2024-02-29 date: 2024-02-29 date: 2024-02-23 date: 2024-02-26 name: Sheffield Children's NHS Foundation Trust class: OTHER name: National Institute for Health Research, United Kingdom name: Sheffield Hallam University name: UCL Great Ormond Street Institute of Child Health name: Leeds General Infirmary briefSummary: This study will help determine if an Interactive Virtual Reality system can improve the physiotherapy of young patients with Duchenne muscular dystrophy (DMD). conditions: Duchenne Muscular Dystrophy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 14 type: ACTUAL name: IVR platform trial measure: Compliance: Ratings of frequency of the DMD-IVR device use for the participant's to complete recommended physiotherapy exercises. measure: Compliance: Ratings of duration of the DMD-IVR device use for the participant's to complete recommended physiotherapy exercises. measure: Post-trial qualitative interviews on perceptions, acceptability, usability and effectiveness of DMD-IVR device in the context of the family's overall burden of care measure: DMD-IVR Effectiveness standard functional assessments: North Star Ambulatory Assessment (NSAA) measure: DMD-IVR effectiveness measures with a Timed test 4 stair climb measure: DMD-IVR effectiveness measured joint range of movement using Goniometer (Standard BASELINE® 12-inch) sex: ALL minimumAge: 5 Years maximumAge: 10 Years stdAges: CHILD facility: Sheffield Childrens NHS FT city: Sheffield state: South Yorkshire zip: S10 2TH country: United Kingdom lat: 53.38297 lon: -1.4659 hasResults: False
|
<|newrecord|> nctId: NCT06274970 id: 2022-143-Mch-EXP-50 briefTitle: PaThERAS: ERAS Protocols in Thyroid & Parathyroid Surgery acronym: PaThERAS overallStatus: RECRUITING date: 2023-01-25 date: 2024-09-25 date: 2024-09-25 date: 2024-02-23 date: 2024-02-23 name: Sanjay Gandhi Postgraduate Institute of Medical Sciences class: OTHER_GOV briefSummary: Enhanced recovery after surgery protocols are evidence-based multidisciplinary programs implemented in the perioperative setting to improve postoperative recovery and attenuate the surgical stress response. They have been used with success after many different types of surgery to improve perioperative patient outcomes. However, evidence on their effectiveness in thyroid and parathyroid surgery remains sparse. Goal of PaThERAS study is to investigate the clinical benefits and cost-effectiveness of enhanced recovery protocols for the perioperative management in patients undergoing total thyroidectomy for large goiters/ cancers and parathyroidectomy for symptomatic hyperparathyroidism in non-day-care setting. conditions: Thyroid Diseases conditions: Parathyroid Diseases conditions: ERAS studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 110 type: ESTIMATED name: Enhanced recovery protocols name: Conventional Protocols measure: To compare the rate of hypocalcemia in patients undergoing thyroid and parathyroid surgery implementing Enhanced recovery after surgery protocols vs Conventional peri operative protocols measure: To compare length of hospital stay in patients undergoing thyroid and parathyroid surgery in days measure: To compare hospital costs in patients undergoing thyroid and parathyroid surgery implementing Enhanced recovery after surgery protocols vs Conventional peri operative protocols measure: To compare postoperative complication rates in patients undergoing thyroid and parathyroid surgery implementing Enhanced recovery after surgery protocols vs Conventional peri operative protocols measure: To compare readmission rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sanjay Gandhi Post Graduate Institute of Medical Sciences status: RECRUITING city: Lucknow state: Uttar Pradesh zip: 226014 country: India name: Gaurav Agarwal role: CONTACT phone: 8004904646 email: [email protected] name: Rinelle Mascarenhas role: CONTACT phone: 8004904653 email: [email protected] name: Gaurav Agarwal, MS role: PRINCIPAL_INVESTIGATOR name: Rinelle Mascarenhas, DNB General Surgery role: SUB_INVESTIGATOR lat: 26.83928 lon: 80.92313 hasResults: False
|
<|newrecord|> nctId: NCT06274957 id: SaglikBilimleriUN briefTitle: The Effect of Airway and Chest Wall Oscillation on Respiratory Functions in COPD Patients in Acute Exacerbation overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-05-07 date: 2024-06-01 date: 2024-02-23 date: 2024-04-17 name: Saglik Bilimleri Universitesi class: OTHER name: Gulhane Training and Research Hospital briefSummary: Chronic obstructive pulmonary disease (COPD); It is a common, treatable and preventable disease characterized by progressive and irreversible airflow limitation and has systemic effects with respiratory system involvement. Increased respiratory workload, decreased work . conditions: COPD Exacerbation Acute studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 27 type: ESTIMATED name: CONTROL name: PEP DEVICE name: HFCWO DEVICE measure: COPD assessment test measure: Clinical COPD Questionnaire measure: mMRC dyspnea scale measure: Richard-Campbell Sleep Questionnaire measure: 30 second sit and stand measure: BODE index measure: chest circumference measurements measure: Modified Borg Scale measure: muscle strenght test sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Health Sciences city: Istanbul zip: 34353 country: Turkey name: ZUHAL KUNDURACILAR PROF DR role: CONTACT phone: +90 530 219 5286 email: [email protected] name: GAMZE KOYUTÜRK PT, PhD(c) role: CONTACT phone: +90 5065798671 email: [email protected] name: GAMZE KOYUTÜRK PT, PhD (C) role: PRINCIPAL_INVESTIGATOR lat: 41.01384 lon: 28.94966 hasResults: False
|
<|newrecord|> nctId: NCT06274944 id: PEDS-2023-31694 briefTitle: Nasogastric/Orogastric Tube Placement Confirmation in Neonates Utilizing Self-contained pH Device, a Feasibility Study overallStatus: RECRUITING date: 2024-02-12 date: 2025-01-31 date: 2025-01-31 date: 2024-02-23 date: 2024-03-04 name: University of Minnesota class: OTHER briefSummary: This study is looking at using a self-contained pH device that will assist in confirming placement of a nasogastric or orogastric tube placed in the stomach of hospitalized infants. conditions: Premature Birth studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: nasogastric tube placement pH confirmation device measure: PH reading comparison sex: ALL maximumAge: 2 Years stdAges: CHILD facility: University of Minnesota status: RECRUITING city: Minneapolis state: Minnesota zip: 55414 country: United States name: Brittany Faanes role: CONTACT lat: 44.97997 lon: -93.26384 hasResults: False
|
<|newrecord|> nctId: NCT06274931 id: 373 briefTitle: Analysis of the Pulmonary Microbiome overallStatus: RECRUITING date: 2024-02-01 date: 2024-02-20 date: 2024-06-20 date: 2024-02-23 date: 2024-02-23 name: University Magna Graecia class: OTHER briefSummary: The purpose of the protocol is to study the pulmonary microbiome in patients who develop pneumonia. conditions: Pneumonia conditions: Microbial Colonization conditions: Microbial Disease studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: Bronchoscopy measure: Assessment of Lung Microbiome in Acute Respiratory Failure sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hosp[ital status: RECRUITING city: Catanzaro zip: 88100 country: Italy name: Andrea Bruni role: CONTACT phone: 3401414553 email: [email protected] lat: 38.88247 lon: 16.60086 hasResults: False
|
<|newrecord|> nctId: NCT06274918 id: 202111418 briefTitle: Reducing ESKAPE Transmission in the Operating Room overallStatus: RECRUITING date: 2023-02-01 date: 2024-06-01 date: 2024-12-01 date: 2024-02-23 date: 2024-02-23 name: University of Iowa class: OTHER name: RDB Bioinformatics, LLC name: Georgia-Pacific briefSummary: This study is designed to examine the impact of a personalized, body worn alcohol dispenser on the epidemiology of ESKAPE transmission in the anesthesia work area for patients undergoing surgery requiring general anesthesia. conditions: Surgical Procedure, Unspecified studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 40 type: ESTIMATED name: Personalized Body-Worn Alcohol Dispenser measure: ESKAPE transmission events with and without the body worn device measure: The epidemiology of ESKAPE transmission events measure: The epidemiology of ESKAPE transmission events measure: The epidemiology of ESKAPE transmission events measure: The epidemiology of ESKAPE transmission events measure: The epidemiology of ESKAPE transmission events measure: 90-Day Healthcare-Associated Infections sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Iowa status: RECRUITING city: Iowa City state: Iowa zip: 52242 country: United States name: Randy W Loftus, MD role: CONTACT lat: 41.66113 lon: -91.53017 hasResults: False
|
<|newrecord|> nctId: NCT06274905 id: 160123 briefTitle: Topical Anaesthesia in Cutaneous Head and Neck Surgery overallStatus: COMPLETED date: 2023-02-20 date: 2023-07-07 date: 2023-07-07 date: 2024-02-23 date: 2024-02-23 name: University Hospital Waterford class: OTHER briefSummary: This study aims to assess if EMLA or ethyl chloride spray are effective in reducing the pain associated with local anaesthetic administration in cutaneous surgery of the head and neck compared to a placebo and control group through a randomized control trial study design. conditions: Pain, Acute conditions: Head and Neck Cancer conditions: Cutaneous Tumor studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Single blinding (for participants) only for patients receiving EMLA or EMLA placebo. whoMasked: PARTICIPANT count: 124 type: ACTUAL name: EMLA name: Ethyl chloride name: Aqueous cream BP measure: Pain score measure: Patient satisfaction sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Waterford city: Waterford zip: X91 ER8E country: Ireland lat: 52.25833 lon: -7.11194 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2022-12-20 uploadDate: 2024-02-06T12:37 filename: Prot_SAP_000.pdf size: 417714 hasResults: False
|
<|newrecord|> nctId: NCT06274892 id: 23-5818 briefTitle: Remote Monitoring of Patient Reported Outcomes to Improve the Efficacy of the Acute Phase Radiotherapy Review Process acronym: PROMOTE overallStatus: RECRUITING date: 2024-04-01 date: 2024-08-31 date: 2024-11-30 date: 2024-02-23 date: 2024-04-17 name: University Health Network, Toronto class: OTHER briefSummary: Radiation therapy (RT) is a key component in the treatment of breast and prostate cancer. However, patients may experience significant side effects. Patients can accurately self-report side effects from RT and these patient-reported outcomes (PROs) can direct communication between patient and healthcare provider (HCP), and facilitate joint decision making.
|
Patients state that using mobile phone applications (apps) to collect PROs (mPROs) is easily incorporated into their daily routines, allowing them to engage at a time and pace that suits them. When mPRO collection is combined with remote symptom monitoring by HCPs, these systems result in improvements in symptom control and quality of life.
|
Currently, patients receiving RT are seen by a Radiation Oncologist once per week during RT and once every few months after RT has finished. Recent evaluations indicate that patients and physicians consider the number of visits to be too frequent during RT, and too infrequent immediately after RT. This research will use weekly mPROs (remotely monitored by RT HCP) to determine if a patient needs (or wants) to be seen by a RT HCP during and/or immediately after RT.
|
Using mPROs to optimize RT patient assessment processes will ensure patients are seen if and when required. For a patient, this could result in reduced time and costs at the hospital. For the physician, resources could be re-allocated to improve access to RT services. Using mPROs after RT has the potential for earlier treatment of side effects, which has been linked to improved survival and quality of life. conditions: Prostate Cancer conditions: Breast Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 124 type: ESTIMATED name: Remote monitoring PROs measure: Remote monitoring efficiency measure: Remote monitoring efficacy measure: Remote monitoring value measure: Remote monitoring comprehensiveness measure: Influencing factors (patient) measure: Influencing factors (disease) measure: Influencing factors (treatment) measure: Influencing factors (toxicity) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Princess Margaret Cancer Centre status: RECRUITING city: Toronto state: Ontario zip: M5G 2J9 country: Canada name: Tara Rosewall role: CONTACT phone: 4162098269 email: [email protected] name: Winnie Li role: CONTACT phone: 4169462000 email: [email protected] lat: 43.70011 lon: -79.4163 hasResults: False
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.